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Abstract 
P2X7 is an intriguing ionotropic receptor for which the activation by extracellular ATP 
induces rapid inward cationic currents and intracellular signalling pathways associated with 
numerous physiological processes such as the induction of the inflammatory cascade, the 
survival and proliferation of cells. In contrast, long-term stimulation of P2X7 is generally 
associated with membrane permeabilization and cell death. Recently, P2X7 has attracted great 
attention in the cancer field, and particularly in the neoplastic transformation and the 
progression of solid tumours. A growing number of studies were published; however they 
often appeared contradictory in their results and conclusions. As such, the involvement of 
P2X7 in the oncogenic process remains unclear so far. The present review aims to discuss the 
current knowledge and hypotheses on the involvement of the P2X7 receptor in the 
development and progression of solid tumours, and highlight the different aspects that require 
further clarification in order to decipher whether P2X7 could be considered as a cancer 
biomarker or as a target for pharmacological intervention. 
 
 
Key words:  
P2X7, extracellular ATP, cancer, biomarker, pharmacological target 
 3
 
1. Introduction 
 
The purinergic signalling, mediated by multiple receptors called P1 and P2 purinoreceptors 
upon extracellular stimulation by adenine nucleoside and nucleotide di- or triphosphates 
respectively, represents very dynamic and plastic mechanisms for controlling a diversity of 
crucial biological functions of cells and tissues such as cell-to-cell communications, secretory 
activities, membrane excitability, cell proliferation, cell differentiation and maturation, cell 
adhesion and migration, and cell death. P1 and P2 receptors are expressed in a large number 
of eukaryotes and particularly at the plasma membrane of virtually every mammalian cell [1]. 
P1 receptors are seven-transmembrane segments (7TM) G-protein coupled receptors and 
commonly termed adenosine receptors because they are physiologically activated by 
nanomolar levels of extracellular adenosine. P2 receptors can be divided into two subfamilies, 
P2X and P2Y receptors, based on their pharmacology and the different downstream signalling 
pathways they are associated with. The P2Y receptors are also 7TM G-protein coupled 
receptors, for which the activating ligands include ATP and some other purine or pyrimidine 
di- or tri-phosphate nucleotides such as ADP, UTP or UDP, and activation initiates signalling 
pathways dependent on the G-proteins they are coupled to [2]. There are eight P2Y subtypes 
in human cells, which can be further subdivided into two groups; P2Y1, P2Y2, P2Y4, P2Y6 
and P2Y11 are coupled to Gq and activation of these receptors stimulates the phospholipase C 
(PLC)-IP3-Ca
2+ signalling pathways, and P2Y12, P2Y13, and P2Y14 are Gi-coupled receptors 
and their activation leads to inhibition of adenylyl cyclase (AC). P2Y11 receptor is also 
coupled to AC stimulation. [3]. By contrast, P2X receptors are ionotropic receptors which are 
physiologically and exclusively activated by extracellular ATP [4]. The P2X receptor family 
is composed of seven members with a membrane topology of two-transmembrane segments 
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(TM1 and TM2) separated by a large extracellular loop for the binding of ATP. P2X receptors 
were proposed to be homo- or hetero-trimeric [5]. This has been confirmed in recent studies 
performed using X-ray crystallography to resolve the three-dimensional structure of the 
zebrafish P2X4 receptor [6, 7]. P2X receptors constitute functional non-selective cation 
channels and their activation mediates very rapid cellular effects, generally resulting in a 
depolarizing inward current due to a major influx of Na+ and Ca2+ into the cytosol at 
physiological membrane potential, while a minor but concomitant efflux of K+ is generated. 
Besides this direct effect on the transmembrane polarity, P2X receptors further contribute to 
important increases in the intracellular Ca2+ concentration by activation of voltage-gated Ca2+ 
channels as a result of membrane depolarization [8] and therefore activate intracellular Ca2+-
dependent signalling pathways that can have longer-term effects [9], and there are possibly 
other signalling pathways following K+ efflux [10]. Some P2X receptors have also been 
identified in intracellular compartments, such as the P2X4 which is also localized in the 
lysosomes of some cells such as macrophages, microglia and endothelial cells [11, 12]. 
Having a clear overview on all the signalling pathways activated, in a tissue, as a function of 
time is important to better understand the very complex resulting biological responses to 
extracellular ATP exposure. Indeed, all cells generally express numerous P1 and P2Y receptor 
subtypes and many excitable and non-excitable cells are also known to express P2X receptors. 
It has to be considered that P2 receptors are activated in specific ranges of purines in 
experimental conditions when agonists are exogenously applied; some receptors such as 
P2Y2 receptor and P2X1 receptor are highly sensitive to nanomolar or submicromolar 
concentrations of ATP, where some others, like P2X7 receptor, are much less sensitive and 
need more than 100 micromolar concentrations to record their activation in vitro [2, 5, 13]. 
However, considering a tissue in physiological conditions, there is no specific range of ATP 
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concentration, even a very small one that would only activate a sole receptor subtype in a 
particular cell type. 
A question naturally arises when one thinks on the purinergic signalling: what is the 
biological origin for these nucleotide ligands? Nucleotides can be released by cells 
constitutively or in response to either mechanical or chemical stimulations. When only 
considering ATP, mechanisms for its release into the extracellular compartment are multiple 
[14] and can be classified into i) transmembrane diffusion, ii) vesicular exocytosis and iii) cell 
lysis-related release. Depending on the considered release mechanism, extracellular ATP can 
reach different concentrations and therefore activates different combinations of P2 receptors, 
at least at the initial time. The vesicular release is a physiological cell-to-cell interaction 
mechanism that is classically associated with neurotransmission and leads to the exocytosis of 
micromolar concentrations of ATP in restricted domains and the activation of post-synaptic 
and pre-synaptic P2 receptors in close vicinity. However, the vesicular release of ATP could 
occur from many non-neuronal cell types such as endothelial cells [15], urothelial cells [16], 
fibroblasts and epithelial lung cancer cells [17], astrocytes [18], osteoblasts [19] 
The transmembrane diffusion of ATP through channels, such as pannexins- or connexins-
composed hemichannels, maxi-anion or volume-regulated anion channels, P2X7 receptors or 
ATP-Binding Cassettes (ABC) transporters, could result in a pericellular halo of low 
micromolar ATP concentration that is involved in the regulation of cell functions via an 
autocrine and/or paracrine fashion. In comparison, cell damage is responsible for much higher 
extracellular concentrations and the establishment of an ATP gradient possibly activating P2 
receptors in multiple cells being in different distances from release site. Furthermore, ATP 
can also be synthesized extracellularly by ecto-adenylate kinases or nucleotide diphosphate 
kinase [20]. The life time of extracellular ATP is tightly controlled by multiple ecto-enzymes 
such as ectonucleotidases and nucleotide diphosphokinases that convert ATP to ADP and 
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adenosine [21]. The presence and activity of such ectonucleotidases can terminate ATP-
evoked signalling but can initiate distinctive signalling pathways by the stimulation of ADP-
sensitive P2 receptors and adenosine receptors. The adenosinergic pathway plays an important 
role in cancer progression since extracellular adenosine generated after extracellular ATP 
hydrolysis by the ectonucleotidases CD39 and CD73 is immunosuppressive, resulting in 
tumour progression, metastases appearance, and poor disease outcomes. Indeed adenosine is 
an autocrine or paracrine factor with potent immunoregulatory activity which facilitates 
tumour escape from the immune control.  Targeted therapies toward the adenosinergic 
pathway, such as antibodies recognizing CD73 and CD39, have proven efficacy in mouse 
tumour models [22, 23]. Therefore, the activation of P2 receptors depends on the 
concentration and identity of nucleotides in the extracellular compartment. In such conditions 
it is obvious that extracellular ATP can physiologically and successively activate numerous 
receptors and their associated intracellular signalling pathways. Each of these signalling 
pathways is tightly regulated so that cells and tissues evolve homogeneously. Numerous 
pathologies appeared to be dependent on the deregulations of one or multiple elements of the 
purinergic signalling cascades. One of these pathologies, which recently has drawn increasing 
attention, is the cancer disease, arising from altered purinergic signalling in both cancerous 
and non-cancerous cells in the tumour. Several excellent reviews on this topic were published, 
some of them being listed here [24-28].  
When focusing on solid tumours, several P2 receptors appear to be critical in the promotion 
and/or progression of the cancer [24, 25, 29]. It seems clear from numerous studies that some 
receptors have pro-cancerous activities and that their pharmacological inhibition, once potent 
and specific tools will become available, could represent new opportunities to treat the 
disease. This is certainly the case of the highly ATP- and UTP-sensitive P2Y2 receptor. There 
is compelling evidence to indicate a critical role for this receptor in cancer cell proliferation 
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[30-32] and resistance to apoptosis [33], thus supporting tumour growth, and in cancer cell 
migration [34], invasion [35] and dissemination, therefore promoting tumour metastasis [36, 
37]. P2X5, and probably also P2Y12 receptors, are also strongly expressed by tumour cells 
and seem to mediate cell differentiation, resulting in an anti-proliferative effect in these cells 
(see [25]). 
 
P2X7 is one of the purinergic receptors which has attracted much of the attention during the 
last five years in the context of cancer disease. However, while a growing number of studies 
show the involvement of this particular receptor in the oncogenic process, multiple aspects 
remain unclear so far such as the cells in the tumour which express the P2X7, the conditions 
for its activation in tumour sites, its functionality and the cell properties it is regulating. As 
such, many questions still remain unanswered that limit consideration of the P2X7 as a cancer 
biomarker or as a target for pharmacological intervention. The present review aims to discuss 
the current knowledge and hypotheses on the involvement of P2X7 in the development and 
progression of solid tumours, and highlight the different aspects that will have to be clarified 
with further investigations.  
 
2. ATP in tumour sites 
ATP is present in the range of 3-10 mM in intracellular compartments of cells. The 
extracellular concentration of ATP is much lower. It was estimated that the physiological 
concentration of ATP in blood is in the range of 20-100 nM and is increased after muscular 
exercise [38]. However, the concentration of ATP in tissues is hard to measure or estimate. 
The team of Francesco Di Virgilio (Ferrarra, Italy) has developed a bioluminescent probe, 
called pmeLUC, for the measurement of extracellular ATP both in vitro and in vivo. This 
probe is a plasma membrane luciferase, with the ATP catalytic site facing the extracellular 
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side, which can be transfected in reporter cells that are subsequently inoculated into tissues 
[39] or directly into cancer cells [40]. This was used to show that the extracellular 
microenvironment of tumours contains relatively high concentrations of ATP, in hundreds of 
micromolar range, whereas it is almost undetectable in healthy tissues [41]. While ATP was 
thought to be secreted by cancer cells [41, 42], it has been postulated that the main source for 
ATP could be dependent on dying cells [43] such as those in the perilesional hypoxic regions 
of solid tumours  [44]. 
While exogenously applied ATP was demonstrated to have anti-neoplastic effects [45-50], it 
is also proposed that endogenous extracellular ATP could contribute to cancer progression 
and promote resistance to anticancer treatments [25]. Endogenously released extracellular 
ATP could also play a beneficial role during anti-cancer therapy by stimulating the immune 
system through immunogenic cell death [51]. The beneficial or detrimental role of ATP may 
depend on the mechanisms of cell death, on the type of ATP release, on the concentrations of 
ATP and obviously on the purinergic receptor signalling pathways involved. ATP can derive 
from different compartments of the cell, coming from mitochondria, endoplasmic reticulum or 
cytoplasm [52]. Tumour cells can undergo different types of cell death with both passive 
release or active secretion of ATP. Several mechanisms of ATP secretion in dying, dead or 
stressed cells have been reported [53]. Different programmed cell deaths such as apoptosis, 
autophagic cell death and pyroptosis promote ATP release by dying cells. Moreover, the non-
programmed cell death called necrosis also leads to ATP release. These four ways to die 
promote ATP release via different mechanisms, and can be beneficial with immunogenic 
properties or detrimental with increased proliferation and/or migration of tumour cells. Anti-
cancer therapies may reorient these beneficial versus detrimental potential of ATP release. In 
particular, the use of immunogenic cell death inducers such as chemotherapy agents in cancer 
therapy or infection by oncolytic viruses may favour immunogenic cell death. Indeed, 
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oncolytic viruses were shown to induce secretion of ATP from human cancer cells [54]. 
Extracellular ATP, besides acting as a danger-associated molecular pattern (DAMP) that can 
stimulate anti-tumour immunity, also functions as a find me signal through P2Y2 receptors, 
facilitating rapid attraction of antigen presenting cells to sites of extensive apoptotic cell 
death.  
 
2.1. Necrosis 
ATP may be released by dying cells in response to non-programmed cues, such as the 
necrosis produced by pressure disruption, hypoxic injury, toxins, cancer, infection and 
trauma. Necrosis is characterized by cellular swelling and rupture of the plasma contents [55]. 
These processes activate the innate immune system and can promote a strong sterile 
inflammation through the NLRP3 inflammasome that activates caspase-1 leading to the 
secretion of the mature pro-inflammatory cytokine interleukin (IL)-1ȕ and IL-18. This 
activation may be triggered in part by ATP produced by mitochondria and released from 
damaged cells [56].  
 
2.2. Apoptosis and autophagy 
Cells which die as part of physiological responses, such as apoptotic or autophagic cells, are 
removed from tissues to prevent immune reactions and maintain tissue homeostasis. Although 
apoptotic cell death has been considered to be non-immunogenic, recent studies unravelled 
that several anti-neoplastic agents and irradiations can trigger immunogenic apoptosis in 
particular through the active secretion of ATP [57]. Moreover, cells dying via autophagy can 
trigger pro-inflammatory responses through the release of ATP driving the inflammasome 
activation [40, 51, 58]. Indeed, autophagy has a dual role: it is a survival mechanism 
responding to poor nutritional or stress conditions to avoid cell death (and suppress apoptosis) 
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by degradation of long-lived proteins and damaged organelles [59, 60]. However, under 
certain circumstances, autophagy constitutes an alternative way for cell to dye through the 
autophago-lysosomal pathway [58]. Autophagic cell death induced by nutrient deprivation, 
hypoxia and infectious pathogens is a non-lytic process, with cell budding and characterized 
by caspase-independent autophagosome formation and action of lysosomal proteases. The 
DAMPs released are ATP and the nuclear protein chromatin-binding high mobility group box 
1 protein (HMGB1). Phagocytosis of human cancer cells dying through autophagy was shown 
to trigger activation of the NLRP3 inflammasome and secretion of mature IL-1E in human 
macrophages via an ATP-dependent mechanism [61]. Blockade of K+ efflux during 
phagocytosis, addition of P2X7 antagonist, incubation in the presence of apyrase, or silencing 
NLRP3 protein expression, inhibit IL-1E secretion response [61]. Moreover, in mouse, the 
NLRP3 inflammasome was activated after macrophage engulfment of autophagic dying cells 
[62]. In autophagic dying cells, ATP was released via pannexin-1 channels. Moreover, in 
phagocytosis of autophagic dying cells, both P2X7 activation and subsequent K+ efflux in 
macrophages are obligatory steps for inflammasome activation [62]. A recent report from G. 
Kroemers group has shown that in response to immunological cell death inducers, ATP 
redistributes from lysosomes to autolysosomes and is secreted by a mechanism that requires 
the lysosomal protein LAMP1, which translocates to the plasma membrane in a strictly 
caspase-dependent manner. These findings suggest that caspase- and pannexin-1 channel-
dependent lysosomal exocytosis has an essential role in ATP release in immunological cell 
death triggered by immunogenic chemotherapy [63]. In vivo, chemotherapeutic agents induce 
tumour autophagic cell death which is immunogenic through recruitment of dendritic cells 
and T cells into the tumour via the secretion [40, 51, 61].  
 
 11
In conclusion, it appears particularly important to understand the factors that determine the 
beneficial or pathogenic responses to extracellular ATP on cancer evolution. Extracellular 
ATP concentrations might be a determinant of the final outcome. Indeed it was shown that 
250 nM extracellular ATP, which activates P2Y receptor signalling, does not modulate T 
regulatory cells, whereas 1 mM ATP which more likely activates P2X7, stimulates T 
regulatory cells, enhancing their ability to proliferate and to be immunosuppressive [64]. In 
addition, prolonged release of low amounts of ATP diminishes the capacity of mature 
dendritic cells to initiate type 1 immune responses [65, 66]. 
 
3. Functional particularities of the P2X7 receptor and relevance to the cancer disease 
Among the members of the P2X receptors family, the P2X7 receptor [67, 68] is very unique 
by multiple features, from its molecular structure, to its biophysical and pharmacological 
properties [69]. Even the cells and tissues expressing P2X7 in physiological conditions are 
different from those observed for other P2X. Indeed, P2X1-P2X6 receptors are expressed 
widely, even if not exclusively, in the nervous system [70] where they underlie the 
neurotransmission at post-synaptic sites generating action potentials or at pre-synaptic sites 
modulating neurotransmitter release [9]. In contrast, while the expression of P2X7 receptors 
in glial cells is well accepted [71, 72], its expression in neurons remains a topic of debate 
because of the use of poorly selective antibodies [73, 74]. The well accepted distribution of 
P2X7 receptor is in immune cells coming from the hematopoeitic lineage, such as monocytes, 
macrophages, dendritic cells, B and T lymphocytes, mast cells and epidermal Langerhans 
cells, in which participation of the receptor in the immune response has been extensively 
documented. Particularly, the participation of P2X7 is critical in the inflammation by inducing 
the activation of the inflammasome and caspase-1 with the subsequent release of the pro-
inflammatory IL-1E from Pathogens Associated Molecular Patterns (PAMPs)-primed 
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macrophages and microglial cells [75, 76]. The P2X7 receptor is expressed in bone cells, in 
both osteoblasts [77, 78] and osteoclasts [79], and seems to be critical in the balance 
maintained between osteoblast and osteoclast activities in normal bone [80] as well as 
deregulations occurring in bone-related cancers [81]. Furthermore, P2X7 is expressed in some 
epithelial cells, and especially from exocrine glands. Its expression in submandibular gland 
acini and ducts, as well as its involvement in the salivary secretion in rodents is well 
documented [82, 83]. P2X7 is also expressed in kidney cells [84], and specifically in 
basolateral membranes [85], however its physiological role remains elusive. Taken together, 
these different studies suggest that P2X7 receptors seem to be mainly involved in the response 
to extracellular ATP in non-excitable cells. 
 
As introduced, P2X7 also demonstrates structural, such as the carboxy-terminal end, and 
functional properties, such as the sensitivity to ATP or the membrane permeabilization for 
cationic dyes induced by its stimulation, that are very unique among all P2X. Some of these 
functional particularities have been considered as being hallmarks of the P2X7 receptor, and 
were often used to characterize P2X7 expression or functionality in native cells or in 
heterologous expression systems. More than being solely hallmarks, we believe that they 
could be of biological relevance, and particularly in the context of the cancer progression. 
Furthermore the gene encoding for P2X7 is highly polymorphic and give many splice variants 
exhibiting both structural and functional particularities. These aspects are commented in the 
following sections. 
 
3.1. Gene, splicing variants and single nucleotide polymorphisms (SNPs) 
The human P2X7 is encoded by the P2RX7 (purinergic receptor P2X, ligand-gated ion 
channel, 7) gene located on the locus 12q24.31. The P2RX7 gene comprises 13 coding exons. 
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Ten naturally occurring alternative splicing variants have been identified in humans and have 
been named P2X7A to J [86, 87]. The P2X7A variant is the well-characterized full-length 
receptor [68]. Among the ten, five splice variants (P2X7B, P2X7C, P2X7E, P2X7G and 
P2X7J) are lacking the C-terminal intracellular tail of the receptor. The truncated P2X7B 
seems to display the same pharmacological properties, towards both agonists and antagonists, 
as the P2X7A and to be functional as an ion channel but it is unable to trigger membrane 
permeabilization for large cationic molecules [86], a property referred to as being the pore 
formation and often associated with cell apoptosis. The P2X7I variant is due to a 5-intronic 
splice site and is responsible for a null allele, that is ineffective in inducing membrane 
permeabilization to fluorescent dyes such as ethidium [88].  
The P2X7J variant is a polypeptide composed of 258 amino acid residues and compared to 
the full-length variant it lacks the distal 337 amino acids that correspond to the entire 
intracellular carboxyterminal end, the second transmembrane domain and the distal part of the 
extracellular loop. This variant, which is unable to induce pore formation, has been proposed 
to oligomerize with the full-length P2X7A receptor and to act as in dominant negative fashion 
[87]. This variant was identified in cervical cancer cells and was proposed to represent a new 
marker for cervical cancer or of defective apoptosis by preventing the cell death due to the 
stimulation of P2X7A by the ATP analogue 3'-O-(4-benzoyl)benzoyl-ATP (BzATP) [89].  
Splice variants have also been identified in rodents. The first identified was termed P2X7k 
and is results from using alternative exon 1 in the rodent P2XR7 gene. This variant is fully 
functional and bears a different N-terminal extremity and first transmembrane domain 
conferring an increased sensitivity to agonists, and slower deactivation kinetics compared to 
the human variants [90]. There are also two variants, P2X7 13B and P2X7 13C, that are 
truncated in the C-terminus, due to an alternative splicing in the exon 13. These two variants 
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displayed a low membrane addressing, low channel function and no membrane 
permeabilization [91].  
Therefore, depending on the splice variants considered the biophysical properties of the 
receptor, its surface expression, as well as interacting molecules and downstream signalling 
pathways could be highly different, and this might be of importance in the cancer. 
 
The human P2X7 receptor is highly polymorphic, and numerous single nucleotide 
polymorphisms (SNPs) have been identified in the last years. While a vast majority of these 
SNPs are located into intronic sequences, about 150 non-synonymous SNPs (NS-SNPs) have 
been reported. Some of these variants have drawn a lot of attention and were particularly 
studied following genetic association studies that proposed them as important genetic factors 
altering the susceptibility of individuals to various diseases [92, 93]. Some of these NS-SNPs 
are responsible for alterations in functional properties of the human receptor, which were 
mostly assessed by recording inward currents and/or dye uptake. The V76A, R117W, L191P, 
T357S, E496A or G150R, E186K, R276H, R307Q, I568N polymorphisms are responsible for 
partial or complete loss-of-function receptors, respectively, while the mutations H155Y, 
H270R and A348T are responsible for gain-of-functions [94-100]. 
Many of these polymorphisms were postulated to be involved in the aetiology of different 
pathologies [92], however, only the 1513A>C polymorphism (rs3751143), resulting in the 
loss-of-function E496A substitution was further studied in the context of the cancerous 
disease. It was initially proposed to be associated with familial B-cell chronic lymphocytic 
leukaemia (CLL) and to contribute to the pathology by inhibiting the P2X7-dependent 
apoptotic signalling pathway [101, 102]. Authors of these studies found that the 1513C allele 
frequency was significantly higher in familial CLL patients than in patients with sporadic 
CLL or in normal subjects coming from the Australian population [102] and proposed that the 
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presence of this polymorphism could have a prognostic significance. However, such an 
association has not been supported by subsequent studies performed in Swedish [103] or 
British cohorts [104, 105], and no correlation was found between the existence of this 
polymorphism in the P2RX7 gene in CLL patients and their clinical outcome, characterized 
by the time between the first diagnosis of the disease and the initiation of chemotherapy 
[106]. Besides, the frequency of this polymorphism studied in samples coming from patients 
with multiple myeloma was not significantly different from that found in normal healthy 
subjects. There was no effect of the 1513A>C polymorphism on the clinical prognostic 
markers and survival in multiple myeloma [107].  
Only two studies were performed to study the prevalence of SNPs in the P2X7 gene in solid 
tumours. The first one was performed in papillary thyroid cancer (PTC) in which the 
expression of two P2X7 polymorphisms was analyzed in lymphocytes from 121 patients. 
While the heterozygous expression of the 1513A>C polymorphism was not significantly 
different in the PTC patient group versus healthy subjects, it was found a very strong increase 
of the homozygous expression in patients suffering from the follicular histological variant of 
PTC. In detail, 13.6% of patients with follicular PTC were homozygous for the 1513C 
polymorphism compared with 2.6% of patients with the classical variant of PTC and 2% of 
healthy subjects. Furthermore, a positive correlation was identified between the 1513A>C 
polymorphism and TNM stage and overall tumour aggressiveness [108]. This would suggest 
that a loss-of-function of the receptor could be favourable for cancer progression. 
The second study was very recently performed in the context of prostate cancer, and led to an 
opposite hypothesis. Indeed a genetic analysis was performed in the P2X7 gene for studying 
well characterized SNPs, and it was found a significant association of the 1513A>C 
polymorphism leading to a loss-of-function of the receptor in low grades of prostate cancers 
while the major allele seemed to be associated with aggressive stages [109].  
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3.2. General structure of the P2X7 receptor 
The P2X7 receptor, like other P2X, is functional under a multimeric assembly of three 
subunits [110, 111]. Each subunit bears a dolphin-like three-dimensional topology as 
predicted by the X-ray crystallography analyses performed on the zebrafish P2X4 receptor in 
the closed and ATP-bound open states [6, 7] and subsequent structural modelling [69]. In line 
with other P2X, the P2X7 subunit consists of a large, glycosylated and cysteine-rich 
extracellular domain composed of 285 amino acids, two transmembrane-spanning helices 
called TM1 and TM2 domains, a short intracellular N-terminal domain and an intracellular C-
terminal domain. The TM1 and TM2 domains in the human P2X7 comprise residues T28-S47 
and N332-L354, respectively. One structural particularity of P2X7, being responsible for 
multiple functional specificities, is the fact that with 595 amino acid residues the P2X7 
protein is significantly bigger than any other P2X subunit. This difference in the protein size 
is solely due to the C-terminal domain which is longer than those of all other P2X subunits by 
containing from 70 to 220 more residues [5].   
The C-terminus of P2X7 has been implicated in regulating receptor function and sub-cellular 
localization, but also in protein-protein interactions and the initiation of intracellular 
signalling cascades [112]. Of importance, it was demonstrated that the P2X7 C-terminus 
possesses a microdomain (P582-Y595) containing a canonical motif YxxI (Y588-S589-
G590-F591). This motif was critical for the receptor targeting to basolateral membranes of 
epithelial cells, and that its deletion or mutations of key amino acid residues induced the 
targeting to the apical membrane [85]. Since P2X7B and P2X7J variants are truncated in the 
C-terminus, they are devoid of this basolateral motif, and changes in their specific expression 
in epithelial cancer cells could interfere with epithelial cell physiology and could be 
responsible or associated with neoplastic transformation. 
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3.3. Sensitivity to ATP  and allosteric modulation of P2X7 
While the mammalian P2X7 orthologs exhibit important differences in their agonist 
sensitivity, the rat P2X7 being 3~10-fold and 30~100-fold more sensitive to ATP and BzATP, 
respectively, than the human [68, 113] and mouse receptors [114], they all constitute the less 
sensitive P2 receptors to extracellular ATP. Residues and motifs involved in P2X7 sensitivity 
to both ATP and BzATP in the different mammalian orthologs were recently reviewed [69]. 
Experimentally, when acutely activated by exogenous ATP, hundreds of micromolars are 
required to record P2X7-mediated currents, Ca2+ increases or P2X7-related dye uptake [5] and 
there are only few biological conditions for which such high concentrations can be reached, 
the more likely being due to the local release of ATP content by dying cells or when 
ectonucleotidases are down-regulated [115]. Thus P2X7 was thought to mostly be activated in 
threatening situations such as infections and tissue injuries.  
However, it has been proposed that P2X7 could also be allosterically modulated in different 
manners. In such conditions, the receptor could display a higher sensitivity and could 
potentially be activated in vivo in lower concentrations of ATP in the extracellular 
compartment. As an example, the mouse P2X7 can be activated by extracellular nicotinamide 
adenine dinucleotide (NAD). This activation of the receptor can be independent of, or in 
synergy with, ATP binding via ADP-ribosylation of the residue R125, catalyzed by the 
activity of ADP-ribosyltransferase 2 ecto-enzymes [116, 117]. Residue R125 is proposed to 
be located in close vicinity with the putative ATP-binding site and ADP-ribosylation would 
favour the binding of the ADP moiety to this site and thereby activate the receptor [117]. The 
corresponding residue in the human P2X7 is also predicted to project towards the ATP-
binding site supporting the hypothesis that ADP-ribose binds to the same site as ATP [118].   
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The antimicrobial peptide LL-37 coming from the maturation of cathelicidin hCAP18, the 
only cathelicidin found in human, was also postulated to activate the P2X7 receptor through a 
mechanism that is not fully understood. Indeed, LL-37 was initially demonstrated to promote 
the processing and release of IL-1ȕ from monocytes [119] and to prevent the apoptosis of 
neutrophils through the activation of P2X7 [120]. Later on, it was shown that LL-37 could 
activate human P2X7 receptors, as assessed as P2X7-dependent dye uptake and intracellular 
calcium increase, heterologously expressed in HEK293 cells and native receptors expressed in 
murine NIH3T3 fibroblasts and this way leading to an increase in cell proliferation [121]. 
Importantly, LL-37 exhibits a helix-forming propensity due to the specific distribution of 
positively and negatively charged residues allowing for the formation of intramolecular salt 
bridges [122]. Thanks to this helicoidal structure, LL-37 is postulated to insert deeply into, 
and to affect eukaryotic membrane integrity [123]. It was therefore suggested that the 
aggregation of LL-37 in the plasma membrane may be involved in the activation of P2X7 
[121]. Interestingly, it has been shown that while LL-37 is present at the surface of normal 
epithelial cells, it is highly over-expressed in both mRNA and proteins in different tumours 
such as breast, lung, prostate, ovary cancers and melanoma. Furthermore, it seems that it is 
synthesized by cancer cells and not by stromal cells, and that its expression is significantly 
higher in biopsies of high than in low histological grades of tumours [124-128]. LL-37 was 
shown to increase metastatic development in immunodeficient SCID mice inoculated with 
human cancer cells [129]. Conversely, LL-37 could participate in the activation of immune 
cells and thereby the anticancerous response of the organism [130, 131]. These different 
properties have been postulated to be under the regulation of P2X7 receptors (see section 5), 
either expressed by cancer or immune cells of the tumours. Thus, it can be postulated that LL-
37 exerts its cancerous effects through the allosteric modulation of P2X7 receptors. 
Alternatively, it is possible that other allosteric modulators from the tumour 
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microenvironment, not yet identified, could act on P2X7 to increase its sensitivity to ATP in 
vivo. 
 
3.4. P2X7 receptor function : ion channel and pore dilatation  
3.4.1. P2X7 receptor ion channel properties 
Activation of P2X7, like all other members of the P2X receptor family, opens within 
milliseconds a transmembrane ion-conducting pathway that is selectively permeable to small 
cations such Ca2+, Na+ and K+ [67, 68].  As mentioned above, opening of the P2X7 receptor 
ion channel can mediate extracellular Ca2+ entry into the cell to elevate the intracellular Ca2+ 
concentrations, and also intracellular K+ efflux or movement out of the cell.  For ligand-gated 
Ca2+-permeable ion channels like the P2X receptors including the P2X7, the ion channel 
functional properties can be studied using the patch-clamp recording technique to directly 
measure agonist-induced ionic currents through open channels (e.g., [113]).  An alternative 
and widely-used means is using fluorescent Ca2+ indicators, such as Fura-2 or Fluo-4, to 
monitor agonist-induced increases in the intracellular Ca2+ concentrations resulting from 
extracellular Ca2+ influx and thereby indirectly characterize the Ca2+-permeable ion channel 
functions (e.g., [132]). The ion channel properties of P2X7 have several biophysical 
properties that contrast with the other P2X receptors. A unique functional property of the 
P2X7 receptor ion channels is that they display no or little desensitization in the presence of 
agonist even for several tens of seconds or minutes, in contrast with the complete 
desensitisation of the P2X1 and P2X3 receptors within a few seconds and the strong 
desensitization of P2X2, P2X4 and P2X5 receptors during tens of seconds [5, 132]. Also, the 
P2X7 receptor ion channels exhibit no discernible rectification, that is, the open channels 
permit ions to move into or out of the cell with similar easiness (e.g., [133]). 
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The most striking particularity of P2X7-mediated currents, compared to all other members of 
the P2X family [5] and to all other ligand-gated ionotropic receptors, is the absence of current 
desensitization to agonist application. Instead, P2X7-mediated currents are incredibly 
increasing in amplitude upon repeated brief applications or sustained application of agonists, 
and this is associated with an increase in the sensitivity to the agonist and was called 
facilitation [133-135]. As detailed previously, a structural particularity of P2X7 compared to 
all other P2X members, is the existence of a 200 residues-long intracellular carboxyterminal 
end that is involved in both receptor functional regulations, by post-translational 
modifications, cellular localization and protein interactions, and signalling pathway activation 
[112]. From the initial studies describing P2X7, it was demonstrated that the C-terminus was 
critical in regulating gating properties [67, 68]. The offset (deactivation) kinetics of P2X7-
mediated currents were also known, from the initial characterization of the receptor, to be 
dependent on the C-terminus and to differ from rat to human orthologs [68]. It was also 
known for long that the P2X7 was the only P2X receptor to show such incredible current 
amplitude and onset kinetics increases during both prolonged and repeated agonist 
stimulations [67, 68, 136]. These increases in current amplitudes and activation kinetics are 
also accompanied by an increase in the agonist sensitivity during the facilitation process 
[135]. However, insights into the molecular mechanism supporting such biophysical 
properties appeared quite recently and remain so far incomplete. It was demonstrated that the 
rat P2X7 presented both Ca2+-dependent and Ca2+-independent facilitation processes. Indeed 
the Ca2+-dependent facilitation was due to the binding of Ca2+-calmodulin (CaM) to a 17-
residues-long 1-5-16 calmodulin binding motif between I541 and R557. Such a motif is 
different from the well-known IQ or IQ-like motifs as it is characterized as being Ca2+-
dependent, meaning that CaM needs to coordinate four Ca2+ ions at each of its EF-hands, 
before to bind to the motif. The combined substitutions I541T and S552C in the C-terminus of 
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the rat P2X7 resulted in the complete loss of CaM binding to the receptor and the Ca2+-
dependent facilitation, without affecting the Ca2+-independent facilitation or the increase in 
agonist sensitivity [135]. Interestingly, only the rat receptor, among all mammalian and non-
mammalian P2X7 cloned up to now, seems to bear such a CaM-binding site. Indeed, the 
human receptor was shown to only possess an important current facilitation process that was 
Ca2+-independent. However, when substituting three residues of the human C-terminus, 
T541I, C552S and G559V, a CaM-binding motif and a Ca2+-dependent facilitation, similar to 
what is observed with the rat receptor, were introduced. This indicates that the change in 
human receptor conformation, following Ca2+-CaM binding and responsible for the increase 
in current amplitude, was also possible [134]. The molecular process responsible for the Ca2+-
independent facilitation is still unknown but seems to be independent on the receptor 
addressing to the membrane. However, another domain of the C-terminus, close to the TM2 
and composed of 18 amino acids (from C372 to V389) and containing 6 cysteine residues, 
was described to be determinant. This cysteine-rich domain is highly conserved between 
species, and its deletion in the rat sequence resulted into the complete loss of facilitation. This 
mutant also showed higher agonist sensitivity and slower deactivation kinetics compared to 
the WT receptor [134]. Thus, it is speculated that the increase in agonist sensitivity during 
current facilitation is correlated to the Ca2+-independent process, found in all orthologs. It 
could also be postulated that this cystein-rich domain acts as a hinge region for the control of 
conformational changes of the receptor during both Ca2+-dependent and Ca2+-independent 
facilitation. This same region was also demonstrated to be critical in receptor dilatation and 
permeability to N-methyl-D-glucamine (NMDG), but not in the dye uptake [137]. A separate 
study describes such increased current responses as sensitization, and proposes that it results 
from the difference in the conductive state of the ion channel arising from the different 
number of ATP molecules bound to the P2X7 receptor [138]. 
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While the molecular mechanisms involved in P2X7 facilitation / sensitization are not fully 
characterized, such a process, along with the absence of desensitization, must be taken into 
account when thinking on the biological functions of P2X7 in vivo. Indeed, this could explain 
an activity of the receptor in vivo under low but constant concentrations of extracellular ATP 
that could be released through an autocrine/paracrine mechanism, and not only it would 
maintain but exacerbate plasma membrane depolarization and signalling pathways dependent 
on P2X7 activation.   
 
3.4.2. P2X7 receptor activation-induced pore formation  
P2X7 is perhaps best known for its capacity to induce a phenomenon called membrane 
permeabilization that refers to the formation of large pores that allow passage of large cationic 
molecules up to 900 Da across the plasma membrane [67, 68]. Due to this unique functional 
property, this receptor was initially named P2Z receptor to separate from other P2X receptors 
before molecular cloning [139]. The large pores appear after the activation of P2X7 for tens 
of seconds to minutes. The time-course or kinetics of the large pore formation or dilation can 
be determined using patch-clamp recording in bi-ionic extracellular and intracellular 
solutions; upon prolonged application of agonist, there is a progressive increase in the 
permeability of the plasma membrane to organic cations, such as NMDG [67, 68, 137], which 
are much larger in size than the physiological cations such as Ca2+, Na+ and K+. The large 
pore formation can be demonstrated under more physiological conditions by monitoring 
progressive efflux of preloaded fluorescent dyes, for example, calceine [140], and more 
commonly, accumulation of extracellular fluorescent dyes, such as YO-PRO-1 (e.g., [141]) 
and ethidium (e.g., [98]), inside the cells during receptor activation. The latter is widely 
referred to as fluorescent dye uptake. 
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Two fundamentally distinctive pore-forming mechanisms have been proposed to explain how 
the large pore forms following P2X7 receptor activation [5]. The first and widely recognized 
mechanism is that separate protein(s) constitute the NMDG-permeable or dye uptake pores 
and the pores open upon activation of P2X7 via physical interactions or conformational 
coupling. There is evidence to support the hemichannel composed of pannexin-1 proteins as 
being the pore-forming unit [140, 142-144]. The second mechanism entails that the large pore 
is an intrinsic functional property of the P2X7 receptor, resulting from progressive dilatation 
of the small ion-conducting pathway. Such a mechanism offers single and satisfactory 
interpretations of the remarkable effects on the large pore-forming capacity and dynamics 
induced by diverse structural difference or disturbances [67, 90, 145, 146]. This is also 
supported by a recent study showing that P2X7 receptor ion channels carrying mutations in 
the ion-conducting pathway are able to pass molecules with sizes up to 14 Å [133].  
Therefore, both mechanisms have gained strong support by various studies so far.  It is worth 
pointing out that these mechanisms are mutually exclusive and in fact, a multiple of pore-
forming mechanisms have been proposed [147]. It is also worth mentioning that formation of 
large pores occurs after activation of some other homomeric or heteromeric P2X receptors, 
including P2X2, P2X4, P2X2/3 and P2X2/5 [148-150] and via different pore-forming 
mechanisms.  For example, there is evidence to suggest no major role of pannexin-1 channel 
in the pore formation induced by activation of the recombinant P2X2 receptor in HEK293 
cells [151] or endogenous P2X4 receptor in microglia [152]. 
 
3.5. P2X7 pharmacology and ligands: potential cancer therapeutic strategies? 
The first three mammalian P2X7 receptors were molecularly identified in 1996-1997 [67, 68, 
136]. Compelling evidence emerged from subsequent studies using transgenic P2X7 deficient 
mice and derived cells supports an important role for the P2X7 receptor in mediating ATP-
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induced generation of IL-1E, a key proinflammatory cytokine, and in the pathogenesis of 
arthritis and chronic pain [153-155]. These findings prompted huge interest in search for 
potent and selective P2X7 receptor ligands. ATP and BzATP still remain the agonists 
available up to date. As mentioned above, BzATP, an ATP synthetic analogue, exhibits a 
greater potency at the P2X7 receptor than ATP with an opposite order of potency at the other 
P2X receptors [13]; such a unique agonist profile has been widely used to indicate functional 
expression of P2X7 receptors, but both ATP and BzATP are not useful therapeutic agents, 
because of their rapid degradation by ubiquitously expressed and membrane-delimited 
enzymes, such as ecto-nucleoside triphosphate diphosphohydrolases. In contrast, several 
potent P2X7 antagonists have been discovered over the past decade, some of which show 
striking selectivity among P2X7 receptors of different mammalian species [69]. KN-62, 
initially identified as a Calmodulin-kinase II inhibitor  [156], was also characterized as being 
the first potent human P2X7 selective antagonist versus other P2X receptors with an IC50 of 
40-100 nM, to which the rat P2X7 receptor is largely insensitive [157].  Brilliant blue G 
(BBG) is the first potent rat P2X7 selective antagonist with an IC50 of 10 nM, which is 
slightly less potent at the P2X7 receptor of other species origins [158].  Systemic 
administration of BBG in rodents reduced tissue loss and improved motor function following 
spinal cord injury [159], and prevented development of morphine tolerance [160], suggesting 
that pharmacological intervention of P2X7 receptor is a promising therapeutic approach. A 
number of medicinal chemistry programmes have led to discovery of several series of drug-
like compounds with distinctive structural properties as highly selective human P2X7 
antagonists with nanomolar potency. Representative examples shown in Figure 1 include 
A438079 and A83997 (tetrazole or trizole-based compounds); A740003, A759029 and 
A804598 (cyanoguanidine derivatives); AZ10606120 (an adamantane amide); AZ11645373 
(a cyclic imide); CE-224535 (an azauracil derivative). 
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As discussed above, prolonged activation of P2X7 receptors causes cell death and there is 
some evidence suggesting such a cytolytic effect may bring therapeutic benefits to certain 
cancerous conditions such as human hematopoietic malignancies including chronic 
lymphocytic leukaemia (CLL) [161]. Heterologous expression in K562 cells of the N187D 
mutant P2X7 receptor, identified in human J6-1 leukaemia cells, accelerated cell proliferation 
and reduced BzATP-induced cell death [162].  Moreover, the tumours developed faster, with 
the size and weight becoming larger and heavier, in immune-deficient mice implanted with 
cells expressing the mutant receptor. These observations suggest enhancing P2X7 receptor 
activity may slow down the pathogenesis and progression of CLL and thus be beneficial. 
Our recent studies, on the other hand, have shown that selective inhibition using KN-62 and 
A740003 of the human P2X7 receptor endogenously expressed in the highly invasive breast 
cancer MDA-MB-435s cells and human lung cancer A549 cells prohibited ATP-induced cell 
migration and particularly cell invasiveness in vitro and in vivo [132, 163].  In addition to 
synthetic chemicals developed by medicinal chemistry, active compounds from traditional 
remedies prepared using plants and other natural sources could be used in therapies. For 
example, emodin (1,3,8-trihydroxy-6-methylanthraquinone) is an anthraquinone derivative, 
extracted from the rhubarb Rheum officinale Baill that has been used in Chinese traditional 
medicine for centuries, and is known to exhibit antitumour properties as well as anti-
inflammatory and immunosuppressive properties, albeit the underlying mechanisms 
appearing multiple [132, 164-166]. Our initial study showed that emodin is a potent P2X7 
antagonist, inhibiting ATP-induced macrophage cell death [167].  In the following study, we 
have further demonstrated that emodin suppressed the invasiveness of breast MDA-MB-435s 
and lung A549 cancer cells through antagonism of the human P2X7 receptor [132]. These 
studies provide clear evidences to indicate an important role for the P2X7 receptors in 
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mediating cancer cell metastasis, the major cause for high mortality. These studies also 
showed proof of concept that pharmacological inhibition of the P2X7 receptors as a 
promising therapeutic strategy. P2X7 antagonists have been tested in clinical trials for 
treatment of rheumatoid arthritis, osteoarthritis, chronic obstructive pulmonary disease and 
inflammatory bowel disease. It is clear that it becomes interesting to test in pre-clinical studies 
and clinical trials P2X7 antagonists, which have proved to be clinically safe such as CE-
224535 and emodin, in treatment of some epithelial cancers, such as breast cancer.  
 
4. Expression and functional properties of P2X7 receptors in solid tumours 
In most types of cells endogenously or heterogeneously expressing P2X7, the 
pharmacological activation of the receptor using high concentrations of ATP or BzATP was 
generally associated with dramatic cellular events such as membrane permeabilization and 
blebbing, loss of asymmetric distribution in phosphatidyl serine, cell swelling, increase of 
internal Ca2+, loss of mitochondrial potential [168, 169]. These entire phenomena were 
demonstrated to be reversible when the agonist applications were brief, and were associated to 
what was called pseudoapoptosis. However, these events were eventually leading to cell 
death upon a prolonged stimulation (more than 30 minutes) [169]. This latter aspect was 
reminiscent to the initial properties associated with the cytolytic function of extracellular ATP 
due to this same receptor [170-173]. These particularities initially led to formulate the 
hypothesis that P2X7 over-expression could be deleterious for cells [67, 169, 174, 175] and 
that stimulating its activity could represent new clinical therapies for treating cancers [50].  
During the last decade, multiple studies assessed the expression levels of P2X7 in different 
cancer biopsies and cancer cell lines. P2X7 expression seemed to be decreased in some 
studies while others reported a very high increase of mRNA, proteins, or both in several 
tumours compared to corresponding normal tissues. However, the full functional 
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characterization of the receptor was very often questioned and rarely provided, thus limiting 
the hypotheses on its participation in oncogenic processes. 
 
4.1. Expression levels in solid tumours and association with tumour grade/tumour 
progression 
 
4.1.1. Breast cancer 
There are contradictory results in assessing the expression of P2X7 in both biopsies and cell 
lines. An initial study on breast cancer was performed to identify the protein expression of 
P2X7 by immunohistochemistry (IHC) on 40 haematoxylin and eosin (H&E) stained samples 
of different histological categories including normal, hyperplastic tissues as well as lobular 
carcinoma in situ, ductal carcinoma in situ, invasive lobular and invasive ductal carcinoma 
[176]. Normal and hyperplastic breast epithelial samples were completely devoid of P2X7 
expression, while all studied cases of in situ or invasive lobular or ductal carcinoma were 
intensely labelled. However, only cancer cells from invasive carcinomas had membrane 
labelling of P2X7, while cancer cells from in situ carcinoma seemed to only show 
intracellular immunoreactivity. While this initial study was very important, it was not 
specified what molecular part of the receptor was used as an antigen for the antibody used. As 
such it is not clear whether the IHC signal obtained is referring to one or multiple P2X7 
variants, and particularly if this antibody was also recognizing the C-terminus truncated 
variants. Although the functionality of P2X7 was not assessed in invasive carcinomas, authors 
were still under the influence of the cytolytic hypothesis on the cellular role of the receptor. 
They postulated that an attempt was being made to induce apoptosis [176], suggesting in a 
deterministic evolutionary conception, that following the carcinogenetic transformation 
cancer cells have initiated the apoptotic process, but unsuccessfully. However, authors 
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proposed that P2X7 expression could be used in order to identify and differentiate early stages 
of breast cancers from hyperplastic lobules [176].  
Correlatively to the initial IHC, some studies proposed that P2X7 could be over-expressed 
during the breast cancer initiation or progression and become functional at the plasma 
membrane of cancer cells. Indeed, the expression of both mRNA and proteins for P2X7 was 
identified in the highly invasive human breast cancer cell lines MDA-MB-435s, while it was 
very weakly or not expressed in non-cancerous mammary epithelial cells HMEC, MCF-10A 
and 184A1 [132, 163]. Furthermore, P2X7 was found to be fully functional at the plasma 
membrane of MDA-MB-435s cells, giving rise to ATP-induced inward currents, increases in 
intracellular calcium concentrations ([Ca2+]i) and ethidium uptake, that were prevented by 
antagonists of P2X7 or by specific small interfering RNA [132, 163]. It was indicated that the 
variant expressed was the full length P2X7A. However, the expression of other variants was 
not addressed. In line with this hypothesis, P2X7 proteins were also detected in highly 
invasive MDA-MB-231 breast cancer cells [177]. In weakly invasive MCF-7 cancer cells, 
messengers RNA were amplified and while proteins could be detected in Western blotting 
experiments [177], the stimulation of cells with high concentrations of ATP was ineffective in 
inducing P2X7-related inward currents suggesting that the receptor could not be functional at 
the plasma membrane [34].  
In contrast with these studies, an IHC study performed with 26 breast carcinoma samples, 13 
ductal carcinomas and 3 lobular carcinomas indicated a tendency for a reduced expression of 
the full-length P2X7 in cancer biopsies [178]. Another recent study examined the protein 
expression of P2X7 by IHC, using an antibody recognizing the carboxyterminal end of the 
receptor, in 80 paired-samples breast biopsies and found that P2X7 immunostaining was 
reduced in cancer tissues compared to adjacent non tumour mammary tissues [179]. In the 
same study, P2X7 proteins were however identified in both weakly MCF-7 and highly 
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aggressive MDA-MB-231 cancer cells, but its expression was proposed to be reduced, 
similarly as in cancer biopsies, by the overexpression of the mature oncogene miRNA miR-
150 [179]. 
 
4.1.2. Prostate cancer 
An initial study of a cohort of 116 biopsies, obtained from men aged from 47 to 86 years, and 
confirmed to be cancerous in the range of the Gleason sum score 49, assessed the expression 
of P2X7 proteins by IHC [180]. It was found that all cancer biopsies were positive for P2X7 
expression, with no correlation with the age of patients or with the Gleason score. P2X7 was 
also identified in non-cancerous epithelial cells adjacent to the margins of the tumour; 
however the labelling seemed to be distinct depending on the stage/vicinity of cells to the 
tumours. Indeed P2X7 appeared to be expressed in the nucleus of non-cancerous cells, then 
into the cytoplasm and finally on the apical membrane of cells progressing into the cancer 
phenotype. In comparison, P2X7 was totally absent from prostate tissues coming from 
patients with no evidence of cancer. These results raised the possibility that P2X7 appears 
during the cancerous progression [180]. In a subsequent study, the same team assessed by 
IHC the expression of P2X7 and compared this to levels of the prostate-specific antigen 
(PSA) in prostate cancer biopsies from 174 patients. They found a positive correlation 
between the P2X7 expression and increasing levels of PSA in patients who were later on 
diagnosed to be cancerous by H&E staining. These results further sustained the hypothesis by 
which the expression of P2X7 could represent an early marker for the diagnosis of prostate 
cancer [181]. In these two initial studies, it is not clear whether the P2X7 variant expressed is 
the full-length P2X7A or another alternative splicing variant, and its functionality was not 
assessed. While it is possible that P2X7 is functional at the plasma membrane of prostate 
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cancer cells, the authors still characterised the receptor as being apoptotic and suggested 
that it might be non-functional. 
Ravenna and collaborators assessed the mRNA and protein expression of different markers 
generally associated with inflammation, in both cancer and non-cancer prostate samples 
coming from laser-capture microdissection of biopsies and showing no or low leukocyte 
infiltrate. They found that P2X7 was highly up-regulated in cancer cells compared to non
cancer cells from the adjacent host tissue and that this was correlated to the over-expression of 
cancer proliferative receptors Epidermal Growth Factor Receptor (EGFR) and Estrogen 
Receptor (ER)D. Authors suggested that a whole pattern of proteins usually associated with 
inflammatory or reparative functions are up-regulated in cancer cells of transformed tissues, 
devoid of detectable leukocyte infiltrate, and could contribute to the cancer progression [182].  
 
4.1.3. Lung cancer 
To date there is no paper assessing the expression of P2X7 in cancer versus non-cancer lung 
biopsies with the aim of studying possible correlations with cancer progression and clinical 
grades. However, there are several in vitro studies relating the expression of P2X7 in human 
lung cancer cells, such as in A549, PC-9 and H292 but not in non-cancerous BEAS-2B 
bronchial epithelial cells [132, 183, 184], suggesting that P2X7 could be up-regulated during 
the malignant transformation of lung epithelial cells.   
 
4.1.4. Pancreatic cancer 
The mRNA expression of P2X7 and the presence of proteins were analysed in chronic 
pancreatitis (samples from 11 patients) and pancreatic cancer (samples from 28 patients) and 
compared to normal pancreas tissues. P2X7 was significantly up-regulated at the mRNA level 
in biopsies of chronic pancreatitis compared to normal pancreas and to pancreatic cancer. At 
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the protein level, P2X7 was not significantly increased in both pancreatic cancer and chronic 
pancreatitis biopsies compared to normal pancreas. In conclusion, P2X7 was not significantly 
overexpressed in pancreatic cancer, and seemed to be mainly expressed by infiltrating 
leukocytes in the pancreas [185].  
 
4.1.5. Papillary Thyroid Cancer (PTC) 
In an initial study performed on the thyroid cancer, the mRNA for P2X7 was found to be 
about two times more abundant in 37 human papillary thyroid cancer samples when compared 
with contralateral non-cancer tissues. Furthermore, immunochemistry was also performed 
with anti-P2X7 antibodies and P2X7 proteins were shown to be strongly expressed in all 
cancerous tissues tested, both in classical and in follicular histological forms of the cancer, 
while they were not present in normal thyroid tissue of the same individual. Malignant 
thyrocytes showed a diffuse P2X7 labelling into the cytoplasm as well as intense labelling at 
the cell periphery. P2X7 mRNA and functional proteins were also expressed in FB1 and FB2 
human thyroid cancer cell lines in which stimulation by both ATP and BzATP enhanced the 
release of the IL-6 [186]. IL-6 local expression is related to the aggressiveness of PTC [187] 
and P2X7 could therefore participate in the development of such a cancer phenotype. The 
over-expression of the full-length P2X7 in PTC was confirmed in another IHC study 
performed with 4 samples [178]. In a subsequent IHC study performed with 43 PTC samples 
compared to 19 samples coming from nodular goiter, it has been demonstrated that the 
expression of both the X-linked inhibitor of apoptosis (XIAP) and the P2X7 was increased in 
PTC samples. Furthermore, P2X7 expression was associated with an increased in the tumour 
size as well as with capsular infiltration and lymph node metastases. Authors of the study 
proposed that P2X7 may represent a predictor of the aggressiveness of PTC [188]. Recently, 
P2X7 protein expression was studied by IHC in 170 biopsies of PTC patients, 84 of which 
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having the chronic autoimmune thyroid disease Hashimotos thyroiditis (HT) and the other 86 
without HT. The expression of P2X7 was significantly higher in the absence of HT and 
correlated with poor prognostic factors such as tumour multifocality, lymphovascular 
invasion and extra-thyroid extension [189]. In conclusion, P2X7 seems to be over-expressed 
in PTC and associated with the aggressiveness of the disease. 
 
4.1.6. Skin cancers  
Skin cancers are histologically subdivided into non-melanomas, which comprise basal cell 
and squamous-cell carcinomas, and melanomas. Squamous cell carcinomas are more frequent 
and more aggressive than basal cell carcinomas since they can give rise to distant metastases. 
Melanoma is the more dangerous and aggressive skin cancer, which initiates after the 
cancerous transformation of melanocytes and has a high potential for metastasis.  
 
Basal-cell and squamous-cell carcinomas 
The expression of P2 receptors was assessed by IHC analysis in human biopsies of basal cell 
and squamous cell carcinomas, and P2X7 was found to be expressed, especially in the 
necrotic center of nodular basal cell carcinomas and in apoptotic cells in superficial multifocal 
and infiltrative basal cell carcinomas. P2X7 is also expressed in the human A431 squamous 
cell carcinoma cell line [190] and, while its functionality was not demonstrated, stimulation 
with high doses of ATP, ATPJS and BzATP reduced cell numbers in vitro [190]. With these 
results, authors claimed that P2X7 was involved in the ATP-mediated apoptosis in cancer 
cells.  
 
Melanoma 
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In an IHC study performed on 80 biopsies coming from patients with superficial spreading 
melanomas, the P2X7 protein was reported to be over-expressed in cancer versus non-cancer 
samples. This increase in P2X7 labelling was also extended to 2µm layer of non-cancerous 
keratinocytes of the epidermis surrounding the tumour [191]. Another study performed in 14 
specimens of human melanoma with an antibody recognizing a C-terminal epitope in P2X7, 
came to confirm these initial results. Indeed, it showed that all melanoma samples expressed 
P2X7, and over 75% of cancer cells in the biopsy were stained positively [30]. Again, these 
results could suggest that P2X7 is over-expressed during the neoplastic transformation of 
keratinocytes. Authors of these two separate studies indicated P2X7 as a potential melanoma 
marker. The receptor was associated with apoptosis [30] and was even proposed that 
melanoma cell proliferation overwhelmed the apoptotic defence [191].   
Data obtained from our group indicated that mRNA expression of P2X7, among other P2X, 
can be detected by RT-PCR in Skmel28, Bris, HBL, 518A2 human melanoma cell lines 
(Figure 2). The presence of proteins and their activity at the plasma membrane was not 
assessed so far. P2X7 mRNA and proteins were also identified in human melanoma cell lines 
such as the A375 [30], and in the murine B16 melanoma cell line [192] in which the variant 
expressed is P2X7a and not the P2X7k variant [193] that exhibits a higher ligand sensitivity 
[90]. 
 
4.1.7. Brain cancers 
Neuroblastoma 
Neuroblastomas are malignant tumours of the childhood that mainly originate from 
embryonic nerve cells in the sympathetic nervous system. In 2006, it was shown, by IHC 
using an antibody targeting the last 20 amino acids of the receptor, that P2X7 proteins were 
expressed in neuroblastoma primary tumours. The vast majority of cancer cells in the tumour 
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displayed an intense labelling. The number of the samples analyzed was moderate but the 
majority of tumours showed high P2X7 expression irrespectively of the histological grade of 
the disease (localized versus metastatic). P2X7 proteins were also detected in the cytosol of 
numerous human neuroblastoma cell lines such as ACN, GI-CA-N, HTLA-230, GI-ME-N, 
LAN-5, LAN-1, SK-N-BE-2 and SH-SY-5Y, and at the plasma membrane of at least ACN 
cells [42]. Even though more characterizations are needed, it can be nonetheless postulated 
that this immunostaining is representative of the expression of a non-C-terminus truncated 
variant, such as the P2X7A. 
 
Glioma 
Gliomas are malignant primary tumours of the central nervous system, deeply infiltrating 
adjacent tissues in the brain, and patients bearing these tumours have a very poor prognosis. 
The principal therapy actually used for the management of disease is the surgical resection of 
the tumour, and there are attempts in improving the efficacy of other treatments such as 
radiotherapy by manipulating the purinergic signalling. In this context there are several in 
vitro experiments that have been performed in either human or rat glioma cell lines. As such 
P2X7 is expressed, in mRNA and proteins, in human U-138MG, U-251MG and M059J, in rat 
C6 and in mouse GL261 glioma cells [194-197]. To date, there is no study comparing the 
levels of P2X7 in human glioma versus non-glioma samples. 
 
4.1.8. Colorectal cancers 
In an IHC study performed with a limited number of human samples, full-length P2X7 
immunoreactivity was identified in the basolateral side of the normal epithelium, while in 
colon adenocarcinoma, the immunoreactivity was distributed throughout the cells. In all the 
five cases studied, P2X7 levels were similar between cancer cells and normal cells [178]. 
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P2X7 was also identified in human HCT8, Caco-2 and murine MCA38 (P2X7a but not k 
variant) and CRC MC-26 colorectal cancer cell lines [193, 198, 199]. 
 
4.1.9. Ovarian cancer 
In a recent study, P2X7 proteins were identified by IHC to be in similar levels in biopsies 
from non-cancerous and cancerous human ovarian biopsies [200].  This study also showed 
functional expression of P2X7 at the plasma membrane of SKOV-3 and CAOV-3 ovarian 
carcinoma cells [200].   
 
4.1.10. Uterine cancers 
Uterine cancers certainly represent the cancer types for which there is the less ambiguity so 
far. Indeed, multiple publications, coming from the team of G. Gorodeski, demonstrated that 
mRNA and proteins for the full-length P2X7 were expressed in epithelial cells of normal uteri 
such as endometrial, endocervical and ectocervical tissues, and was reduced in cervical 
squamous cell carcinomas as well as in endometrial and endocervical adenocarcinomas. 
Furthermore, there was a reduced expression of P2X7 in hyperplastic pre-cancerous 
endometrium compared to normal endometrium. These observations have led the authors to 
propose that P2X7 expression could be used as a biomarker for uterine epithelial cancers 
[178, 201, 202]. The reduction in the P2X7 expression was claimed to result from the over-
expression of micro RNA miR-186 and miR-150 in cancer cells [203]. Furthermore, the 
dominant negative P2X7J variant truncated in the C-terminus, was identified in cervical and 
normal cancer cells. The expression levels of P2X7J were very similar in normal and cancer 
cells, but the expression of P2X7A was higher in normal cells. Authors proposed this P2X7J 
variant to represent a new marker for cervical cancer or of defective apoptosis by imposing a 
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dominant negative inhibitory effect on P2X7A and thereby preventing the cell death due to 
the stimulation of P2X7A by BzATP [87, 89]. 
 
5. Role of P2X7 receptors in determining tumorigenesis  
5.1. P2X7 receptors in cancer cells 
 
As indicated in the previous section, P2X7 is often found to be expressed in cancer biopsies 
and cancer cells, and multiple studies have assessed the cellular properties related to cancer 
progression or prevention the receptor could be associated with or even trigger. However, 
depending on the cell types or the ways by which P2X7 were studied, the results appeared to 
strikingly different and sometimes apparently opposite indicating that P2X7 could be pro-
cancerous or even anti-cancerous. A detailed analysis of the method used could be 
informative to highlight apparent discrepancies.  
 
5.1.1. Pro-cancerous activities of P2X7 in cancer cells 
Promoting cell survival, proliferation and tumour growth 
In murine melanoma B16 cells, P2X7 was found to be responsible for the extracellular release 
of ATP in acidic conditions (pH 6.4) mimicking the acidosis found in the core of solid tumour 
as a result of the hypoxia. This release resulting in extracellular ATP in the 10 nM range, 
which was prevented by pharmacological antagonism using A438079 or by expressional 
repression of P2X7 using small interfering RNA (siRNA), was responsible for an increase in 
cancer cell proliferation in vitro. The increase in cell proliferation was due to another 
purinoreceptor than the P2X7, which remains to be identified [192]. Therefore P2X7 was 
indirectly promoting cancer cell proliferation, by releasing extracellular ATP, and its 
pharmacological inhibition using oxidized-ATP (oATP) significantly inhibited the tumour 
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growth of B16-bearing syngenic mice [192]. J-radiations (0.5 Gy) were also proposed to 
induce ATP release by the same melanoma cells partially through P2X7 [204]. 
A P2X7 variant not truncated in its C-terminus, and possibly the P2X7A, is expressed in 
human neuroblastoma biopsy samples and in numerous neuroblastoma cell lines. In ACN 
cells the receptor is expressed at the plasma membrane and is thought to be functional. ATP 
and/or BzATP stimulations induced increases in the [Ca2+]i, plasma membrane depolarization 
and YO-PRO-1 uptake. This latter parameter was prevented by incubation with KN-62 [42]. 
ATP stimulation also caused cell rounding, membrane blebbing and the release of vesicles 
into the extracellular space, without activation of caspase-3. P2X7 activation was associated 
to cancer cell growth through the paracrine release of the trophic substance P from nucleotide-
activated neuroblastoma cells. Further evidence supporting the role of P2X7 in controlling 
cell survival and proliferation of neuroblastoma cells was shown that the treatment of mouse 
neuroblastoma Neuro-2a cells with the ATP hydrolase apyrase or with P2X7 antagonists, 
oATP or BBG, decreased cancer cell viability and cell number. Conversely, the 
pharmacological inhibition of P2X7 in these cells promoted neurite outgrowth and neuronal 
differentiation of cells [205, 206]. One could hypothesize that P2X7 activity in neuroblastoma 
cells maintains an undifferentiated and proliferative phenotype that could be representative of 
cancer cell characteristics and cancer stem cells properties. 
P2X7 is expressed at the plasma membrane of SKOV-3 and CAOV-3 ovarian carcinoma 
cells. In these cells, BzATP stimulation increased the [Ca2+ ]i and the levels of phosphorylated 
Akt (pAkt) and ERK (pERK), which were prevented by the use of A438079. BzATP did not 
induced cell death in these two cell lines. The mechanical stimulation of cells produced by a 
flow of physiological solution was responsible for an increase in the [Ca2+ ]i that was 
abolished in the presence of apyrase, therefore suggesting release of ATP. Furthermore, the 
incubation of cells with apyrase, with the P2X7 antagonist AZ10606120, or their transfection 
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with the P2X7 E496A mutant inducing a dominant negative effect on the wild-type receptor, 
reduced cell viability by about 30%. Taken together these results led the authors to suggest 
that basal activity of P2X7, induced through the auto-release of ATP, increased pERK and 
pAkt levels and maintained cell viability [200]. 
With a series of excellent studies, Adinolfi and Di Virgilio and collaborators demonstrated 
that P2X7 displays a trophic activity in the absence of pharmacological exogenous activation 
[207]. They have proposed the idea that P2X7 could support different cellular aspects that are 
critical to the oncogenic transformation, to cancer cell proliferation and tumour growth 
through a basal activity of the receptor. They initially demonstrated that the transfection of 
Human Embryonic Kidney (HEK293) cells with the full-length human P2X7, having the 
capacity to induce membrane permeabilization, increased the resting mitochondrial potential, 
the basal mitochondrial Ca2+ concentration and the intracellular ATP content, and thus 
enhanced to whole mitochondrial activity which increased cell proliferation and conferred to 
the cells the ability to grow in the absence of serum. These effects were dependent on an 
autocrine/paracrine tonic stimulation by released ATP, as they were abolished in the presence 
of apyrase. On the other hand, the sustained stimulation of P2X7 by exogenous ATP had 
opposite effects and resulted in cell death [208]. Later on, using the same cellular model, they 
demonstrated that P2X7 transfection increased the ability of the endoplasmic reticulum to 
accumulate, store, and release Ca2+. Furthermore, P2X7 expressing cells survived and 
proliferated in serum-free conditions and were resistant to apoptosis triggered by ceramide, 
staurosporin, or intracellular Zn2+ chelation. The nuclear factor of activated T cells complex 1 
(NFATc1) was strongly activated in the P2X7 transfectants in the absence of exogenous 
agonist. All these effects were abrogated in presence of oATP or apyrase, further supporting 
the initial finding that P2X7, under tonic conditions in response to basal ATP release, had an 
anti-apoptotic activity or even promoted cell growth [209]. The P2X7B variant retaining its 
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ion channel activity but unable to induce membrane permeabilization, had similar effects, and 
cells over-expressing this variant showed the ability to infiltrate into soft agar, like tumour 
cells would do. The co-expression of the full-length P2X7A with the P2X7B induced the 
formation of heterotrimers that potentiated all the cellular effects observed in the presence of 
P2X7B alone (i.e. increased intracellular Ca2+ and Ca2+ release from the ER, potentiation of 
NFATc1 activation, increased cell survival and infiltrating colonies) and increased the 
intracellular contents of ATP as well as the release of ATP [146]. They further demonstrated 
that the expression of P2X7 promoted tumour growth in vivo. HEK293 cells expressing P2X7 
exhibited a more tumorigenic and anaplastic phenotype than control cells in vivo when 
inoculated subcutaneously into nude mice. The growth of these tumours was reduced by 
intratumoral injection of oATP. P2X7-expressing tumours secreted high amounts of VEGF 
and showed a more developed vascular network than control tumours. This tumoral growth 
and neoangiogenesis of P2X7-expressing tumours were blocked by intratumoral injection of 
the VEGF-blocking antibody Avastin (bevacizumab), as well as the pharmacologic or 
molecular inhibition of P2X7. Similar results were obtained using mouse CT26 colon 
carcinoma cells transfected with mouse P2X7 receptor inoculated into syngenic 
immunocompetent BALB/c mice. Tumour growth was also inhibited by the blockade of 
P2X7 endogenously expressed in B16 mouse melanoma and in ACN human neuroblastoma 
cells and inoculated to syngenic C57Bl/6 or nude mice, respectively [210].  
 
Induction of pro-invasive properties 
In the rat C6 glioma cell, mRNA and proteins of P2X7 are expressed, and the stimulation with 
BzATP induced an increase in the [Ca2+ ]i and ethidium uptake, that were prevented by the 
incubation with oATP, suggesting that the receptor might be functional. Furthermore, the 
stimulation of C6 cells with BzATP was responsible for the up-regulation of P2X7 mRNA 
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and protein expression. Stimulation with BzATP also induced a four-fold increase in cell 
migration [195]. Another study performed in same C6 cells as well as human U-138MG cells, 
indicated that glioma cells were more resistant to cell death and to the induction of caspase-
3/7 activity upon stimulation with high extracellular concentrations of ATP (5 mM) and 
BzATP (100 µM) in comparison with non-cancerous organotypic  hippocampal slice cultures 
[211]. 
In highly invasive MDA-MB-435s human breast cancer cells was, P2X7 was found to be 
fully functional as activation of the receptor by ATP gave rise to inward currents, increases in 
the [Ca2+]i and, to less degree, ethidium uptake. The activation of the receptor by ATP also 
led to the release of active cysteine cathepsins responsible for the proteolytic degradation of 
the extracellular matrix and promoting cancer cell invasiveness, with very mild effect on cell 
viability [132, 163]. To notice, in these studies, the pharmacological inhibition of P2X7 by 
both competitive and non-competitive antagonists, as well as its reduced expression by the 
use of small interfering RNA significantly inhibited basal invasion in the absence of 
stimulation with an exogenous agonist. This would favour the hypothesis of a basal activity of 
the receptor that could be due to local and autocrine / paracrine release of ATP by cancer 
cells. P2X7 was also expressed in A549, PC-9 and H292 lung cancer cells and its exogenous 
activation by ATP or BzATP, as well as the autocrine release of ATP by cancer cells 
mediated by TGF-E1, also led to the increase in cell invasiveness that was prevented by 
synthetic (A438079) or natural (emodin) antagonists of the receptor [132, 183, 184]. 
Interestingly, the migration of PC-9 cells was under the dependence of EGFR receptors 
harbouring constitutively active mutations, and inhibition of their activity with AG1478 and 
gefinitib inhibited both cell migration and the expression of P2X7 proteins [184].  
 A study indicated that PC-3 human prostate cancer cells express mRNA for P2X7 receptor, 
and while application of ATP was responsible for the inhibition of cancer cell growth and 
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viability, it was not prevented by using the P2X7 antagonist KN-62 and was more likely 
mediated by P2X5 [29]. In this study, it was not clear whether P2X7 was functional, since 
ATP failed to induce membrane permeabilization, assessed by the Lucifer yellow uptake 
assay. However, the ability of the receptor to induce a characteristic ATP-mediated inward 
current was not assessed and the involvement of P2X7 in other cancer properties was not 
specifically studied. In a recent study performed with PC-3 cells, P2X7 was found to enhance 
the invasiveness of DU-145 in PC-3 human prostate cancer cells [109]. These facts question 
on the use of ATP-induced membrane permeabilization as an indicator of P2X7 functional 
expression.  
 
Metabolic adaptation to tumour microenvironment 
Hypoxic episodes occurring in some areas of tumours would stabilize and activate the 
hypoxia-inducible factor-1D (HIF-1D) that would increase the expression of P2X7. In both 
MCF-7 and MDA-MB-231 breast cancer cells, hypoxia induced a HIF-1D-dependent increase 
of P2X7 expression which in turn was responsible for sustaining cancer cell survival and 
invasiveness through the activation of the ERK1/2 and Akt pathways and the extracellular 
activity of MMP-2 and MMP-9 gelatinases [177].  In PC-3 prostate cancer cells hypoxic 
episodes were associated with HIF-1D stabilization and translocation into the nucleus and to 
the increased expression of P2X7 [212] which would also increase cancer cell invasiveness 
[109].  
These results are in line with those obtained in the lab of Di Virgilio showing that the 
overexpression of the full-length P2X7 was responsible for a metabolic adaptation of cells 
towards a glycolytic phenotype, even in aerobic conditions [213]. This phenotype is well 
known as being the Warburg effect and is associated with neoplastic development and cancer 
aggressiveness [214]. This metabolic shift, was characterized by the upregulation of HIF1D, 
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the glucose transporter Glut-1, the glycolytic enzymes glyceraldehydes 3-phosphate 
deshydrogenase G3PDH, phosphofructokinase PFK pyruvate kinase PKM2 and pyruvate 
dehydrogenase kinase 1 PDHK1, along with the reduced expression of the pyruvate 
deshydrogenase PDH, and allowed the cells to proliferate in the absence of serum and in the 
very stringent environmental conditions that could be found in developing tumours [213]. 
 
5.1.2. Anti-cancerous activities of P2X7 in cancer cells  
Induction of Apoptosis 
In MCF-7 and MDA-MB-231 breast cancer cells, P2X7 is proposed to negatively regulate 
cell proliferation and tumour growth by inducing apoptosis and that the reduction of its 
expression by miR-150 which is upregulated in cancer tissues would reduce cancer cell death 
and promote cancer cell and colony growth [179].  
In the human A431 squamous cell carcinoma cell line P2X7 is found to be expressed and, 
while its functionality was not clearly demonstrated, its stimulation with high doses of ATP, 
ATPJS and BzATP reduced cell numbers in vitro. These results, together with the finding that 
P2X7 seemed to be expressed in apoptotic/necrotic foci of basal cell and squamous cell 
biopsies, the authors of the study claimed that P2X7 was involved in the ATP-mediated 
apoptosis in cancer cells [190]. Similarly, P2X7 mRNA and protein are expressed in human 
HCT8 and Caco-2 colon adenocarcinoma cell lines and both ATP (1 mM) and BzATP (100 
µM) increased the [Ca2+ ]i. This was reduced in the presence of oATP or KN-62. Stimulation 
of cancer cells with high concentrations of ATP (2 mM) for 48 hours reduced the cell viability 
as shown by measuring the proportion of hypodiploid cells using flow cytometry. This was 
attributed to the induction of apoptosis in cancer cells. Pre-treatment of cells with oATP 
inhibited this proapoptotic effect of ATP by about 50%, which led the authors to conclude 
that P2X7 was involved in apoptosis of intestinal epithelial cells but another P2 receptor 
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might also contribute [198]. Yaguchi and collaborators also identified that high concentrations 
of ATP reduced Caco-2 cancer cell growth through the inhibition of PKC, but since they were 
unable to identify P2X7 mRNA expression, they proposed that another unknown receptor was 
involved [215]. 
In A375 human melanoma cells, mRNA for P2X7 was detected, and proteins were 
immunostained by using an antibody recognizing an epitope in the C-terminus of the receptor.  
Even though, it remains unknown if these cells express or not other splice variants, the one 
detected was not truncated in the C-terminus and could correspond to the full-length P2X7A. 
The stimulation of cells with hundreds of micromolar BzATP induced membrane 
permeabilization to YO-PRO-1, the activation of caspase-3/7 and resulted in a decrease in cell 
survival. While the co-application of KN-62 only mildly reversed cell death, it was suggested 
that P2X7 activation was pro-apoptotic and that its pharmacological targeting (activation) 
could provide a novel treatment of the disease [30]. Following this hypothesis, they pursued 
with an in vivo model in which athymic mice were subcutaneously inoculated with A375 
human melanoma cells. Mice were then treated with daily intraperitoneal injections of 1 mL 
D-PBS containing 50 mM ATP for 39 days. The tumour volume and animal weight were 
measured over the course of the experiment. The treatment with ATP was shown to decrease 
the tumour volume by 50% in 7 weeks in treated mice, and prevented the weight loss 
observed in untreated animals [216]. These results supported the idea that ATP could be used 
as a treatment for melanoma, but the exact mechanism and the receptors involved in the 
effects observed in this experimental in vivo model were not demonstrated. 
In a model of skin neoplasia induced by the administration of the carcinogenetic and 
promoting agents, DMBA (7,12-dimethyl-benz(a)anthracene) and TPA (12-O-
tetradecanoylphorbol-13-acetate) respectively, on the skin of FVB female mice, it was shown 
that the direct application of BzATP reduced the proportion of living animals bearing 
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tumours, and the size of lesions [217]. This effect was attributed to the induction of apoptosis 
in cancer cells stimulated by 100 µM BzATP.  
No information was given on the expression of the different splice variants and particularly of 
those being truncated in the C-terminus that would be ineffective in inducing membrane 
permeabilization. In in vitro experiments, authors of this study showed that the application of 
100 µM BzATP increased the [Ca2+ ]i, induced membrane permeabilization to ethidium and 
induced apoptosis in normal keratinocytes from wild-type mice , while it failed to induce ATP 
in normal keratinocytes coming from P2X7-/- mice. In chimio-induced cancer tissues, it 
appeared that the expression of the full-length P2X7, monitored by both western blotting and 
immunohistochemistry, was decreased compared to the normal skin. These results prompted 
the authors to conclude the diminished pro-apoptotic effect of BzATP in cancer keratinocyte 
was due to a lower expression of P2X7 as compared to normal keratinocyte. They also 
proposed that the activation of apoptosis in cancer cells through the activation of P2X7 with 
BzATP could represent a novel chemotherapeutic growth-preventing modality for skin 
cancers in vivo [217]. While this study is of sure interest it did not consider the participation 
of other P2 receptors in vivo, and the risk and side effects that could be triggered by such 
treatments. Furthermore, the P2X7 receptor is depicted as a pro-apoptotic receptor being 
down-regulated in cancer cells. Indeed, apoptosis is induced when stimulating the cells with 
high doses of BzATP. However, such pharmacological and prolonged stimulations of P2X7 
can trigger cellular responses that are not the same than those activated by the receptor under 
basal conditions. As such it is possible that such experiments do not allow the determination 
of the real role played by P2X7 in cancer biology. 
 
While the release of low concentrations of ATP (in the 10 nM range), mediated by basal 
activity of P2X7 in B16 mouse melanoma cells, was indirectly inducing an increase in cancer 
 45
cell proliferation, high concentrations of ATP (in the 3 mM range) thus possibly directly 
activating the receptor and inducing membrane permeabilization had opposite effects [192]. 
Therefore the level of ATP released, as well as the mode and time-scale of the activation of 
P2X7, might result in striking different effects. Further supporting this idea, it has been 
proposed that high concentrations of ATP, which could be released by dying cancer cells in 
necrotic areas of tumours, could directly kill adjacent tumour cells via P2X7. Therefore, 
maintaining high concentrations of ATP by inhibiting the ectonucleotidase CD39 would have 
an anti-tumour effect [218]. While such a hypothesis is tempting, it is hard to understand how 
very aggressive tumours, showing multiple necrotic foci, still continue to naturally grow and 
to metastasize.   
In a recent study performed in mouse MCA38 colon adenocarcinoma cells and in mouse B16 
melanoma cells, the P2X7a variant (but not the P2X7k variant) is expressed (mRNA) and the 
stimulation of cells with high doses of ATP (up to 5 mM) and to BzATP (up to 2 mM) was 
responsible for ethidium uptake and for a reduction in cell viability and in clonogenicity. The 
proposed mechanism is a decrease in the intracellular content of ATP and a deregulation of 
the PI3K/Akt and AMPK-PRAS40-mTOR signalling pathways that perturb the balance 
between cell growth and autophagy [193]. 
 
 
Inhibition of cancer cell proliferation and tumour growth 
In C6 rat glioma cells, both the pharmacological (BBG) and the molecular extinction (siRNA) 
were found to have growth promoting effect in vitro and in vivo. These effects were not due to 
a significant reduction in caspase-3 induction in cancer cells, but rather as a consequence of 
the over-expression of EGFR, HIF1-D, VEGF and P2Y2 [196]. In GL261 mouse glioma cells, 
high concentrations of ATP (5 mM) and BzATP (up to 3 mM) induced the uptake of 
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propidium iodide and a rapid increase in extracellular LDH activity, external exposure of 
phosphatidylserine and a reduction of cell survival measured by MTT cell viability assay, 
which were claimed to be mediated by P2X7. These effects were not observed in P2X7-
expressing rat C6 or human U138 and U87 glioma cells [197]. 
The effect of P2X7 agonists, ATP and BzATP, in combination or not with irradiation (2Gy) 
on cell death was studied in human U-138MG, U-251MG and M059J glioma cells. All the 
three cell lines expressed P2X7 proteins, but the radiosensitive M059J glioma cells 
significantly expressed higher levels of proteins, and showed a higher ethidium uptake upon 
ATP (5 mM) stimulation, both in the absence or presence of irradiations, than in the two other 
cell lines. P2X7 agonists produced cell death in the radiosensitive M059J cell line, but the 
radioresistant glioma cell lines U-138MG and U-251MG presented resistance to death when 
treated with either ATP or BzATP [194]. While authors claimed a relevance of P2X7 
activation for increasing glioma radiosensitivity, more experiments are necessary to really 
understand the roles of P2X7 in the acquisition of resistances to therapeutic strategies. 
 
Inhibition of cancer cell migration 
In a recent study, it is shown that P2X7 is expressed in human MDA-MB-231 breast cancer 
cells, however its stimulation by the non-hydrolysable analogue ATPJS reduces cancer cell 
growth, migration, and inhibits the growth of orthotopic xenograft tumours due to the 
injection of same human cells in the mammary fat pad of nude mice [219].  In this same 
study, while the activity of P2X7 was not clearly demonstrated, it was proposed that its 
persistent stimulation with ATPJS reduced mouse Py8119 breast cancer cell migration in vitro 
and tumour growth in a model of intratibial injection of cells in C57bl/6 mice [219]. 
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It is widely accepted that the anti-proliferative or pro-apoptotic effect resulting from 
exogenous stimulation of P2X7 in some cell types are associated with the membrane 
permeabilization property. It can be postulated that, in some cancer cells P2X7 is fully 
functional as an ion channel but not inducing membrane permeabilization, because of the 
expression of a C-terminus truncated variant or due to the molecular uncoupling to pore 
forming channels such as pannexin-1. In such cases, P2X7 would control other cellular 
properties such as cancer cell invasiveness. If this hypothesis can be verified, it can be 
proposed that, selective induction of membrane permeabilization in cancer cells might 
represent a new strategy to treat cancers, probably more specific than the pharmacological 
targeting of P2X7. 
 
5.2. P2X7 receptors in tumour-associated immune cells 
Tumours are infiltrated with different subsets of immune cells and some tumours originate 
from a chronic inflammatory environment, and thus there is a well-orchestrated functional 
interaction among inflammatory infiltrates and the tumour [220, 221]. P2X7 is highly 
expressed and controls the function of different immune cells such as monocytes, 
macrophages, dendritic cells and lymphocytes [222-224]. As detailed in the previous section, 
tumour microenvironment present high levels of extracellular ATP and therefore activation of 
the P2X7 is likely to occur in tumours infiltrated by immune cells. However, P2X7 function 
in tumour-associated immune cells will elicit a pro-tumorigenic response contributing to 
tumour growth and progression by inducing the production of different pro-tumorigenic 
factors such as extracellular matrix-degrading enzymes and other bioactive molecules such as 
VEGF or prostaglandins [225-228]. This is mainly due to the fact that tumour-associated 
macrophages present an M2 alternative activated phenotype associated with tissue 
remodelling and the resolution of the inflammation, where P2X7 function uncouples from 
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pro-inflammatory cytokines production [175, 229, 230]. This event plays a pivotal role in the 
lack of immunity against tumours and the failure to elicit a robust immune response to 
remove cancer cells. Tumour-associated macrophages would be immunosuppressive and 
therefore would prevent the attack of tumour cells by natural killer and T-cells [230]. In this 
context, immunotherapy treatments against tumours aim to elicit a robust pro-inflammatory 
response that will prime innate dendritic cells and macrophages towards M1 inflammatory 
phenotypes for efficient tumour-associated antigen presentation to lymphocytes [231, 232]. In 
this regard, anticancer treatments, such as radiotherapy or some chemotherapeutic agents, 
besides to induce direct cytotoxic effects on cancer cells, they also mediate immunogenic cell 
death and therefore elicit an IFNJ-mediated immune response required for the efficacy of 
these treatments [233, 234]. In the tumour environment dying tumour cells succumbing to 
chemotherapy further increased the activation of P2X7 in macrophages and dendritic cells via 
the release of ATP. This release of ATP in conjunction with Toll-like receptor (TLR) 
engagement with other DAMP signals, such as the HMGB1, are essential to elicit a proper 
anti-cancer immunity [235, 236]. In macrophages and dendritic cells, the activation of these 
pathways converges in the assembly of the inflammasome, a central innate immune sensor for 
pathogens-associated molecular patterns (PAMPs) and/or DAMPs [76, 237, 238]. The 
NLRP3 inflammasome activated via P2X7, has been described as being responsible for 
eliciting CD8+ T-cell mediated cancer eradication following anticancer treatments [51, 236]. 
However, NLRP3 and other inflammasomes, including NLRC4 and NLRP6, have been also 
implicated in tumorigenesis [239]. Therefore in the context of cancer, P2X7 activation during 
tumorigenesis will play different roles in different types of cancers, being beneficial in certain 
circumstances and injurious in others. The use of specific drug-like P2X7 antagonists 
targeting immune cells could be detrimental in the first steps of cancer development by 
inducing an immune tolerogenic response. In contrast, when the primary tumour is 
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established, pharmacological blockage of P2X7 could decrease the tumour-promoting 
function of tumour-associated macrophages [44]. 
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  Conclusions and perspective on future research direction 
From the 1980s, the importance of extracellular adenine nucleotides was demonstrated 
in carcinogenesis. At that time it was demonstrated that the application of exogenous ATP or 
ADP had anti-cancerous properties through the inhibition of cancer cell growth, and ATP or 
BzATP were even proposed as treatment modalities in vivo in animal models and in humans 
[45-49]. This hypothesis was further supported until recently [50]. However, while treatments 
with ATP had very strong cytotoxic effects on cancer cells from several tumours, it also 
appeared that in some other occasions it could have pro-cancerous activities [25]. Besides, 
treatments with ATP or analogs could initiate nociceptive pathways through the activation of 
P2X3 receptors on sensory nerves. These intriguing results prompted researchers to study in 
details the activity and participation of the purinergic signalling, and purinergic receptors, in 
carcinogenesis and in the progression of cancers, as well as the release mode and 
concentrations of nucleotides in the tumour site [26]. Results obtained are of primary 
importance as they could lead to the formulation of novel therapeutic strategies and to the 
repurposing of purinergic receptor antagonists developed for the treatment of other 
pathologies in the cancer treatment. Among all P2 receptors studied in the context of cancer 
initiation and progression, the P2X7 receptor seemed to attract the most of interest and also 
probably generated the most of controversy on its expression, activity and postulated role. 
With the exception of some experiments, among which those performed on uterine cancers, 
most of the studies performed in cancer biopsies and cancer cells indicated the over-
expression of P2X7. Multiple studies appeared contradictory in their results when assessing 
the possible involvement of P2X7 in oncogenic processes. However, a careful analysis of the 
experiments conducted should help in determining such discrepancies, in proposing new 
hypotheses and important aspects of P2X7 properties that will have to be examined in the 
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future studies. A critical point will be to clearly analyse, in cancer cells, the presence and 
intensity of all the functional properties classically attributed to P2X7 (ATP-induced current, 
intracellular Ca2+ increase, membrane permeabilization, etc) as they might be associated with 
different biological functions. It is also obvious that the cells expressing P2X7 in a tumour 
(cancer cells versus non-cancer cells) are important to consider as they might be associated 
with either pro-cancerous or anti-cancerous immune properties. Not only the cells are 
important, but the step of the carcinogenesis or grade of the tumour should be considered. 
P2X7 activation during tumorigenesis could play different roles in different types of cancers, 
being beneficial in certain circumstances, and injurious in others. The use of specific drug-like 
P2X7 antagonists targeting immune cells could be detrimental in the first steps of cancer 
development by inducing an immune tolerogenic response. In contrast, when the primary 
tumour is established, pharmacological blockage of P2X7 could result at least in the decrease 
of the tumour-promoting function of tumour-associated macrophages. It could also reduce the 
pro-cancerous effect of P2X7 function in cancer cells. Future studies will have to determine 
the pattern of expression of the different P2X7 splice variants, not only the expression of the 
full-length P2X7A, in both non-cancerous and cancerous cells, as they could be responsible 
for various or even opposite regulations of biological functions. Such an analysis was recently 
initiated with a study performed in osteosarcoma samples and cells [240]. Authors showed 
that both P2X7A and P2X7B variants were expressed in most osteosarcoma samples analysed 
and that they were responsible for differential effects on cell growth and matrix 
mineralization.  
 
From this overview of the literature, it can be postulated that basal activity of P2X7 in cancer 
cells from an established tumour could be pro-cancerous [146, 208, 210], while the exogenous 
stimulation of P2X7 [50], or the endogenous stimulation following anticancer treatment and 
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cell death [51], with high concentrations of extracellular ATP could be anti-cancerous (Figure 
3). However, it is now understood that the exogenous stimulation of cells with (high) 
concentrations of hydrolysable or non-hydrolysable agonists, for a long period of time, even if 
giving interesting results in vitro, might not reflect what is really happening in tumours in 
vivo. As such, the results obtained might be considered respectfully with these limitations. In 
line with this aspect, it appears that P2X7 could have a basal activity, due the autocrine / 
paracrine release of ATP in concentrations that are supposed to be much lower than those 
used in vitro to stimulate the receptor.  
Furthermore, it can also be postulated that P2X7 expression and functionality in cancer cells, 
together with the endogenous ATP in the tumour, represent key parameters for the selection 
of cancer cells with an aggressive phenotype. This was formulated as being the Run or die 
hypothesis: the increase of the extracellular ATP concentration in the tumour could represent 
a stressful selective pressure for from which many cancer cells would die while some other, 
that do not undergo apoptosis, that are the most invasive, would be selected [44].  
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[ 6 8 ]  F .  R a s s e n d r e n ,  G . N .  B u e l l ,  C .  V i r g i n i o ,  G .  C o l l o ,  R . A .  N o r t h  a n d  
A .  S u r p r e n a n t ,  J  B i o l  C h e m  2 7 2  ( 1 9 9 7 )  5 4 8 2 - 6 .  
[ 6 9 ]  L . H .  J i a n g ,  J . M .  B a l d w i n ,  S .  R o g e r  a n d  S . A .  B a l d w i n ,  F r o n t  
P h a r m a c o l  4  ( 2 0 1 3 )  5 5 .  
[ 7 0 ]  G .  B u r n s t o c k  a n d  G . E .  K n i g h t ,  I n t  R e v  C y t o l  2 4 0  ( 2 0 0 4 )  3 1 - 3 0 4 .  
[ 7 1 ]  G .  C o l l o ,  S .  N e i d h a r t ,  E .  K a w a s h i m a ,  M .  K o s c o - V i l b o i s ,  R . A .  
N o r t h  a n d  G .  B u e l l ,  N e u r o p h a r m a c o l o g y  3 6  ( 1 9 9 7 )  1 2 7 7 - 8 3 .  
[ 7 2 ]  D .  F e r r a r i ,  M .  V i l l a l b a ,  P .  C h i o z z i ,  S .  F a l z o n i ,  P .  R i c c i a r d i -
C a s t a g n o l i  a n d  F .  D i  V i r g i l i o ,  J  I m m u n o l  1 5 6  ( 1 9 9 6 )  1 5 3 1 - 9 .  
[ 7 3 ]  J . A .  S i m ,  M . T .  Y o u n g ,  H . Y .  S un g ,  R . A .  N o r t h  a n d  A .  S u r p r e n a n t ,  
J  N e u r o s c i  2 4  ( 2 0 0 4 )  6 3 0 7 - 1 4 .  
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[ 7 4 ]  C . M .  A n d e r s o n  a n d  M .  N e d e r g a a r d ,  T r e n d s  N e u r o s c i  2 9  ( 2 0 0 6 )  
2 5 7 - 6 2 .  
[ 7 5 ]  D .  F e r r a r i ,  P .  C h i o z z i ,  S .  F a l z o n i ,  M .  D a l  S u s i n o ,  L .  M e l c h i o r r i ,  
O . R .  B a r i c o r d i  a n d  F .  D i  V i r g i l i o ,  J  I m m u n o l  1 5 9  ( 1 9 9 7 )  1 4 5 1 - 8 .  
[ 7 6 ]  F .  D i  V i r g i l i o ,  T r e n d s  P ha r m a c o l  S c i  2 8  ( 2 0 0 7 )  4 6 5 - 7 2 .  
[ 7 7 ]  A .  G a r t l a n d ,  I . R .  O r r i s s ,  R . M .  R u m n e y ,  A . P .  B o n d ,  T .  A r n e t t  a n d  
J . A .  G a l l a g h e r ,  F r o n t  B i o s c i  ( L a n d m a r k  E d )  1 7  ( 2 0 1 2 )  1 6 - 2 9 .  
[ 7 8 ]  A .  G a r t l a n d ,  R . A .  H i p s k i n d ,  J . A .  G a l l a g h e r  a n d  W . B .  B o w l e r ,  J  
B o n e  M i n e r  R e s  1 6  ( 2 0 0 1 )  8 4 6 - 5 6 .  
[ 7 9 ]  A .  G a r t l a n d ,  K . A .  B u c k l e y ,  R . A .  H i p s k i n d ,  W . B .  B o w l e r  a n d  J . A .  
G a l l a g h e r ,  C r i t  R e v  E u k a r y o t  G e n e  E x p r  1 3  ( 2 0 0 3 )  2 3 7 - 4 2 .  
[ 8 0 ]  N . R .  J o r g e n s e n ,  Z .  H e n r i k s e n ,  O . H .  S o r e n s e n ,  E . F .  E r i k s e n ,  R .  
C i v i t e l l i  a n d  T . H .  S t e i n b e r g ,  J  B i o l  C h e m  2 7 7  ( 2 0 0 2 )  7 5 7 4 - 8 0 .  
[ 8 1 ]  E .  A d i n o l f i ,  F .  A m o r o s o  a n d  A . L .  G i u l i a n i ,  J  O s t e o p o r o s  2 0 1 2  
( 2 0 1 2 )  6 3 7 8 6 3 .  
[ 8 2 ]  M .  G a r c i a - M a r c o s ,  S .  P o c h e t ,  A .  M a r i n o  a n d  J . P .  D e h a y e ,  C e l l  
S i g n a l  1 8  ( 2 0 0 6 )  2 0 9 8 - 1 0 4 .  
[ 8 3 ]  S .  P o c h e t ,  M .  G a r c i a - M a r c o s ,  M .  S e i l ,  A .  O t t o ,  A .  M a r i n o  a n d  
J . P .  D e h a y e ,  C e l l  S i g n a l  1 9  ( 2 0 0 7 )  2 1 5 5 - 6 4 .  
[ 8 4 ]  K . A .  H i l l m a n ,  T . M .  J o h n s o n ,  P . J .  W i n y a r d ,  G .  B u r n s t o c k ,  R . J .  
U n w i n  a n d  A . S .  W o o l f ,  E x p  N e p h r o l  1 0  ( 2 0 0 2 )  3 4 - 4 2 .  
[ 8 5 ]  H . J .  B r a d l e y ,  X .  L i u ,  V .  C o l l i n s ,  J .  O w i d e ,  G . R .  G o l i ,  M .  S m i t h ,  
A .  S u r p r e n a n t ,  S . J .  W h i t e  a n d  L . H .  J i a n g ,  F E B S  L e t t  5 8 4  ( 2 0 1 0 )  
4 7 4 0 - 4 .  
[ 8 6 ]  B .  C h e e w a t r a k o o l p o n g ,  H .  G i l c h r e s t ,  J . C .  A n t h e s  a n d  S .  
G r e e n f e d e r ,  B i o c h e m  B i o p h y s  R e s  C o m m u n  3 3 2  ( 2 0 0 5 )  1 7 - 2 7 .  
[ 8 7 ]  Y . H .  F e n g ,  X .  L i ,  R .  Z e n g  a n d  G . I .  G o r o d e s k i ,  N u c l e o s i d e s  
N u c l e o t i d e s  N u c l e i c  A c i d s  2 5  ( 2 0 0 6 )  1 2 7 1 - 6 .  
[ 8 8 ]  K . K .  S k a r r a t t ,  S . J .  F u l l e r ,  R .  S l u y t e r ,  L . P .  D a o - U n g ,  B . J .  G u  a n d  
J . S .  W i l e y ,  F E B S  L e t t  5 7 9  ( 2 0 0 5 )  2 6 7 5 - 8 .  
[ 8 9 ]  Y . H .  F e n g ,  X .  L i ,  L .  W a n g ,  L .  Z h o u  a n d  G . I .  G o r o d e s k i ,  J  B i o l  
C h e m  2 8 1  ( 2 0 0 6 )  1 7 2 2 8 - 3 7 .  
[ 9 0 ]  A .  N i c k e ,  Y . H .  K u a n ,  M .  M a s i n ,  J .  R e t t i n g e r ,  B .  M a r q u e z - K l a k a ,  
O .  B e n d e r ,  D . C .  G o r e c k i ,  R . D .  M u r r e l l - L a g n a d o  a n d  F .  S o t o ,  J  
B i o l  C h e m  2 8 4  ( 2 0 0 9 )  2 5 8 1 3 - 2 2 .  
[ 9 1 ]  M .  M a s i n ,  C .  Y o u n g ,  K .  L i m ,  S . J .  B a r n e s ,  X . J .  X u ,  V .  M a r s c h a l l ,  
W .  B r u t k o w s k i ,  E . R .  M o o n e y ,  D . C .  G o r e c k i  a n d  R .  M u r r e l l -
L a g n a d o ,  B r  J  P h a r m a c o l  1 6 5  ( 2 0 1 2 )  9 7 8 - 9 3 .  
[ 9 2 ]  E . A .  C a s e l e y ,  S . P .  M u e n c h ,  S .  R o g e r ,  H . - J .  M a o ,  A . B .  S t e p h e n  
a n d  L . H .  J i a n g ,  I n t .  J .  M o l .  S c i .  1 5  ( 2 0 1 4 )  1 3 3 4 4 - 1 3 3 7 1 .  
[ 9 3 ]  R .  B a r t l e t t ,  L .  S t o k e s  a n d  R .  S l u y t e r ,  P h a r m a c o l  R e v  6 6  ( 2 0 1 4 )  
6 3 8 - 7 5 .  
[ 9 4 ]  B . J .  G u ,  R .  S l u y t e r ,  K . K .  S k a r r a t t ,  A . N .  S h e m o n ,  L . P .  D a o - U n g ,  
S . J .  F u l l e r ,  J . A .  B a r d e n ,  A . L .  C l a r k e ,  S .  P e t r o u  a n d  J . S .  W i l e y ,  J  
B i o l  C h e m  2 7 9  ( 2 0 0 4 )  3 1 2 8 7 - 9 5 .  
[ 9 5 ]  B . J .  G u ,  W .  Z h a n g ,  R . A .  W o r t h i n g t o n ,  R .  S l u y t e r ,  P .  D a o - U n g ,  
S .  P e t r o u ,  J . A .  B a r d e n  a n d  J . S .  W i l e y ,  J  B i o l  C h e m  2 7 6  ( 2 0 0 1 )  
1 1 1 3 5 - 4 2 .  
[ 9 6 ]  A . N .  S h e m o n ,  R .  S l u y t e r ,  S . L .  F e r n a n d o ,  A . L .  C l a r k e ,  L . P .  D a o -
U n g ,  K . K .  S k a r r a t t ,  B . M .  S a u n d e r s ,  K . S .  T a n ,  B . J .  G u ,  S . J .  
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F u l l e r ,  W . J .  B r i t t o n ,  S .  P e t r o u  a n d  J . S .  W i l e y ,  J  B i o l  C h e m  2 8 1  
( 2 0 0 6 )  2 0 7 9 - 8 6 .  
[ 9 7 ]  G .  C a b r i n i ,  S .  F a l z o n i ,  S . L .  F o r c h a p ,  P .  P e l l e g a t t i ,  A .  B a l b o n i ,  
P .  A g o s t i n i ,  A .  C u n e o ,  G .  C a s t o l d i ,  O . R .  B a r i c o r d i  a n d  F .  D i  
V i r g i l i o ,  J  I m m u n o l  1 7 5  ( 2 0 0 5 )  8 2 - 9 .  
[ 9 8 ]  S .  R o g e r ,  Z . Z .  M e i ,  J . M .  B a l d w i n ,  L .  D o n g ,  H .  B r a d l e y ,  S . A .  
B a l d w i n ,  A .  S u r p r e n a n t  a n d  L . H .  J i a n g ,  J  P s y c h i a t r  R e s  4 4  
( 2 0 1 0 )  3 4 7 - 5 5 .  
[ 9 9 ]  J . S .  W i l e y ,  L . P .  D a o - U n g ,  C .  L i ,  A . N .  S h e m o n ,  B . J .  G u ,  M . L .  
S m a r t ,  S . J .  F u l l e r ,  J . A .  B a r d e n ,  S .  P e t r o u  a n d  R .  S l u y t e r ,  J  B i o l  
C h e m  2 7 8  ( 2 0 0 3 )  1 7 1 0 8 - 1 3 .  
[ 1 0 0 ]  L .  S t o k e s ,  S . J .  F u l l e r ,  R .  S l u y t e r ,  K . K .  S k a r r a t t ,  B . J .  G u  a n d  J . S .  
W i l e y ,  F a s e b  J  2 4  ( 2 0 1 0 )  2 9 1 6 - 2 7 .  
[ 1 0 1 ]  J . S .  W i l e y ,  L . P .  D a o - U n g ,  B . J .  G u ,  R .  S l u y t e r ,  A . N .  S h e m o n ,  C .  
L i ,  J .  T a p e r ,  J .  G a l l o  a n d  A .  M a n o h a r a n ,  L a n c e t  3 5 9  ( 2 0 0 2 )  
1 1 1 4 - 9 .  
[ 1 0 2 ]  L . P .  D a o - U n g ,  S . J .  F u l l e r ,  R .  S l u y t e r ,  K . K .  S k a r R a t t ,  U .  
T h u n b e r g ,  G .  T o b i n ,  K .  B y t h ,  M .  B a n ,  R .  R o s e n q u i s t ,  G . J .  
S t e w a r t  a n d  J . S .  W i l e y ,  B r  J  H a e m a t o l  1 2 5  ( 2 0 0 4 )  8 1 5 - 7 .  
[ 1 0 3 ]  U .  T h u n b e r g ,  G .  T o b i n ,  A .  J o h n s o n ,  O .  S o d e r b e r g ,  L .  P a d y u k o v ,  
M .  H u l t d i n ,  L .  K l a r e s k o g ,  G .  E n b l a d ,  C .  S u n d s t r o m ,  G .  R o o s  a n d  
R .  R o s e n q u i s t ,  L a n c e t  3 6 0  ( 2 0 0 2 )  1 9 3 5 - 9 .  
[ 1 0 4 ]  J .  S t a r c z y n s k i ,  C .  P e p p e r ,  G .  P r a t t ,  L .  H o o p e r ,  A .  T h o m a s ,  T .  
H o y ,  D .  M i l l i g a n ,  P .  B e n t l e y  a n d  C .  F e g a n ,  B r  J  H a e m a t o l  1 2 3  
( 2 0 0 3 )  6 6 - 7 1 .  
[ 1 0 5 ]  L . Y .  Z h a n g ,  R . E .  I b b o t s o n ,  J . A .  O r c h a r d ,  A . C .  G a r d i n e r ,  R . V .  
S e e a r ,  A . J .  C h a s e ,  D . G .  O s c i e r  a n d  N . C .  C r o s s ,  L e u k e m i a  1 7  
( 2 0 0 3 )  2 0 9 7 - 1 0 0 .  
[ 1 0 6 ]  H .  N u c k e l ,  U . H .  F r e y ,  J .  D u r i g ,  U .  D u h r s e n  a n d  W .  S i f f e r t ,  E u r  J  
H a e m a t o l  7 2  ( 2 0 0 4 )  2 5 9 - 6 3 .  
[ 1 0 7 ]  S .  P a n e e s h a ,  J .  S t a r c z y n s k i ,  C .  P e p pe r ,  J .  D e l g a d o ,  L .  H o o p e r ,  C .  
F e g a n  a n d  G .  P r a t t ,  L e u k  L y m p h o m a  4 7  ( 2 0 0 6 )  2 8 1 - 4 .  
[ 1 0 8 ]  A .  D a r d a n o ,  S .  F a l z o n i ,  N .  C a r a c c i o ,  A .  P o l i n i ,  S .  T o g n i n i ,  A .  
S o l i n i ,  P .  B e r t i ,  F .  D i  V i r g i l i o  a n d  F .  M o n z a n i ,  J  C l i n  
E n d o c r i n o l  M e t a b  9 4  ( 2 0 0 9 )  6 9 5 - 8 .  
[ 1 0 9 ]  A .  G h a l a l i ,  F .  W i k l u n d ,  H .  Z h e n g ,  U .  S t e n i u s  a n d  J .  H o g b e r g ,  
C a r c i n o g e n e s i s  3 5  ( 2 0 1 4 )  1 5 4 7 - 5 5 .  
[ 1 1 0 ]  L . E .  B r o w n e ,  L . H .  J i a n g  a n d  R . A .  N o r t h ,  T r e n d s  P h a r m a c o l  S c i  
3 1  ( 2 0 1 0 )  2 2 9 - 3 7 .  
[ 1 1 1 ]  L . H .  J i a n g ,  M .  K i m ,  V .  S p e l t a ,  X .  B o ,  A .  S u r p r e n a n t  a n d  R . A .  
N o r t h ,  J  N e u r o s c i  2 3  ( 2 0 0 3 )  8 9 0 3 - 1 0 .  
[ 1 1 2 ]  H . M .  C o s t a - J u n i o r ,  F .  S a r m e n t o  V i e i r a  a n d  R .  C o u t i n h o - S i l v a ,  
P u r i n e r g i c  S i g n a l  7  ( 2 0 1 1 )  7 - 1 9 .  
[ 1 1 3 ]  H . J .  B r a d l e y ,  L . E .  B r o w n e ,  W .  Y a n g  a n d  L . H .  J i a n g ,  B r  J  
P h a r m a c o l  1 6 4  ( 2 0 1 1 )  7 4 3 - 5 4 .  
[ 1 1 4 ]  M . T .  Y o u n g ,  P .  P e l e g r i n  a n d  A .  S u r p r e n a n t ,  M o l  P h a r m a c o l  7 1  
( 2 0 0 7 )  9 2 - 1 0 0 .  
[ 1 1 5 ]  L . Y .  L e n e r t z ,  M . L .  G a v a l a ,  Y .  Z h u  a n d  P . J .  B e r t i c s ,  I m m u n o l  
R e s  5 0  ( 2 0 1 1 )  2 2 - 3 8 .  
 59
[ 1 1 6 ]  M .  S e m a n ,  S .  A d r i o u c h ,  F .  S c h e u p l e i n ,  C .  K r e b s ,  D .  F r e e s e ,  G .  
G l o w a c k i ,  P .  D e t e r r e ,  F .  H a a g  a n d  F .  K o c h - N o l t e ,  I m m u n i t y  1 9  
( 2 0 0 3 )  5 7 1 - 8 2 .  
[ 1 1 7 ]  S .  A d r i o u c h ,  P .  B a n n a s ,  N .  S c h w a r z ,  R .  F l i e g e r t ,  A . H .  G u s e ,  M .  
S e m a n ,  F .  H a a g  a n d  F .  K o c h - N o l t e ,  F a s e b  J  2 2  ( 2 0 0 8 )  8 6 1 - 9 .  
[ 1 1 8 ]  M . T .  Y o u n g ,  T r e n d s  B i o c h e m  S c i  3 5  ( 2 0 1 0 )  8 3 - 9 0 .  
[ 1 1 9 ]  A .  E l s s n e r ,  M .  D u n c a n ,  M .  G a v r i l i n  a n d  M . D .  W e w e r s ,  J  
I m m u n o l  1 7 2  ( 2 0 0 4 )  4 9 8 7 - 9 4 .  
[ 1 2 0 ]  I .  N a g a o k a ,  H .  T a m u r a  a n d  M .  H i r a t a ,  J  I m m u n o l  1 7 6  ( 2 0 0 6 )  
3 0 4 4 - 5 2 .  
[ 1 2 1 ]  L .  T o m a s i n s i g ,  C .  P i z z i r a n i ,  B .  S k e r l a v a j ,  P .  P e l l e g a t t i ,  S .  
G u l i n e l l i ,  A .  T o s s i ,  F .  D i  V i r g i l i o  a n d  M .  Z a n e t t i ,  J  B i o l  C h e m  
2 8 3  ( 2 0 0 8 )  3 0 4 7 1 - 8 1 .  
[ 1 2 2 ]  J .  J o h a n s s o n ,  G . H .  G u d m u n d s s o n ,  M . E .  R o t t e n b e r g ,  K . D .  B e r n d t  
a n d  B .  A g e r b e r t h ,  J  B i o l  C h e m  2 7 3  ( 1 9 9 8 )  3 7 1 8 - 2 4 .  
[ 1 2 3 ]  K . A .  H e n z l e r - W i l d m a n ,  G . V .  M a r t i n e z ,  M . F .  B r o w n  a n d  A .  
R a m a m o o r t h y ,  B i o c h e m i s t r y  4 3  ( 2 0 0 4 )  8 4 5 9 - 6 9 .  
[ 1 2 4 ]  J . D .  H e i l b o r n ,  M . F .  N i l s s o n ,  C . I .  J i m e n e z ,  B .  S a n d s t e d t ,  N .  
B o r r e g a a r d ,  E .  T h a m ,  O . E .  S o r e n s e n ,  G .  W e b e r  a n d  M .  S t a h l e ,  
I n t  J  C a n c e r  1 1 4  ( 2 0 0 5 )  7 1 3 - 9 .  
[ 1 2 5 ]  S . B .  C o f f e l t ,  R . S .  W a t e r m a n ,  L .  F l o r e z ,  K .  H o n e r  z u  B e n t r u p ,  
K . J .  Z w e z d a r y k ,  S . L .  T o m c h u c k ,  H . L .  L a M a r c a ,  E . S .  D a n k a ,  C . A .  
M o r r i s  a n d  A . B .  S c a n d u r r o ,  I n t  J  C a n c e r  1 2 2  ( 2 0 0 8 )  1 0 3 0 - 9 .  
[ 1 2 6 ]  J .  v o n  H a u s s e n ,  R .  K o c z u l l a ,  R .  S h a y k h i e v ,  C .  H e r r ,  O .  
P i n k e n b u r g ,  D .  R e i m e r ,  R .  W i e w r o d t ,  S .  B i e s t e r f e l d ,  A .  A i g n e r ,  
F .  C z u b a y k o  a n d  R .  B a l s ,  L u n g  C a n c e r  5 9  ( 2 0 0 8 )  1 2 - 2 3 .  
[ 1 2 7 ]  J . E .  K i m ,  H . J .  K i m ,  J . M .  C h o i ,  K . H .  L e e ,  T . Y .  K i m ,  B . K .  C h o ,  
J . Y .  J u n g ,  K . Y .  C h u n g ,  D .  C h o  a n d  H . J .  P a r k ,  B r  J  D e r m a t o l  1 6 3  
( 2 0 1 0 )  9 5 9 - 6 7 .  
[ 1 2 8 ]  J . A .  H e n s e l ,  D .  C h a n d a ,  S .  K u m a r ,  A .  S a w a n t ,  W . E .  G r i z z l e ,  
G . P .  S i e g a l  a n d  S .  P o n n a z h a g a n ,  P r o s t a t e  7 1  ( 2 0 1 1 )  6 5 9 - 7 0 .  
[ 1 2 9 ]  G .  W e b e r ,  C . I .  C h a m o r r o ,  F .  G r a n a t h ,  A .  L i l j e g r e n ,  S .  Z r e i k a ,  Z .  
S a i d a k ,  B .  S a n d s t e d t ,  S .  R o t s t e i n ,  R .  M e n t a v e r r i ,  F .  S a n c h e z ,  A .  
P i v a r c s i  a n d  M .  S t a h l e ,  B r e a s t  C a n c e r  R e s  1 1  ( 2 0 0 9 )  R 6 .  
[ 1 3 0 ]  W . K .  W u ,  J . J .  S u n g ,  K . F .  T o ,  L .  Y u ,  H . T .  L i ,  Z . J .  L i ,  K . M .  C h u ,  
J .  Y u  a n d  C . H .  C h o ,  J  C e l l  P h y s i o l  2 2 3  ( 2 0 1 0 )  1 7 8 - 8 6 .  
[ 1 3 1 ]  A . S .  B u c h a u ,  J  I n v e s t  D e r m a t o l  1 3 0  ( 2 0 1 0 )  9 2 9 - 3 2 .  
[ 1 3 2 ]  B .  J e l a s s i ,  M .  A n c h e l i n ,  J .  C h a m o u t o n ,  M . L .  C a y u e l a ,  L .  
C l a r y s s e ,  J .  L i ,  J .  G o r e ,  L . H .  J i a n g  a n d  S .  R o g e r ,  C a r c i n o g e n e s i s  
3 4  ( 2 0 1 3 )  1 4 8 7 - 9 6 .  
[ 1 3 3 ]  L . E .  B r o w n e ,  V .  C o m p a n ,  L .  B r a g g  a n d  R . A .  N o r t h ,  J  N e u r o s c i  
3 3  ( 2 0 1 3 )  3 5 5 7 - 6 6 .  
[ 1 3 4 ]  S .  R o g e r ,  L .  G i l l e t ,  A .  B a r o j a - M a z o ,  A .  S u r p r e n a n t  a n d  P .  
P e l e g r i n ,  J  B i o l  C h e m 2 8 5  ( 2 0 1 0 )  1 7 5 1 4 - 2 4 .  
[ 1 3 5 ]  S .  R o g e r ,  P .  P e l e g r i n  a n d  A .  S u r p r e n a n t ,  J  N e u r o s c i  2 8  ( 2 0 0 8 )  
6 3 9 3 - 4 0 1 .  
[ 1 3 6 ]  I . P .  C h e s s e l l ,  J .  S i m o n ,  A . D .  H i b e l l ,  A . D .  M i c h e l ,  E . A .  B a r n a r d  
a n d  P . P .  H u m p h r e y ,  F E B S  L e t t  4 3 9  ( 1 9 9 8 )  2 6 - 3 0 .  
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[ 1 3 7 ]  L . H .  J i a n g ,  F .  R a s s e n d r e n ,  A .  M a c k e n z i e ,  Y . H .  Z h a n g ,  A .  
S u r p r e n a n t  a n d  R . A .  N o r t h ,  A m  J  P h y s i o l  C e l l  P h y s i o l  2 8 9  
( 2 0 0 5 )  C 1 2 9 5 - 3 0 2 .  
[ 1 3 8 ]  Z .  Y a n ,  A .  K h a d r a ,  S .  L i ,  M .  T o m i c ,  A .  S h e r m a n  a n d  S . S .  
S t o j i l k o v i c ,  J  N e u r o s c i  3 0  ( 2 0 1 0 )  1 4 2 1 3 - 2 4 .  
[ 1 3 9 ]  P .  P i z z o ,  M .  M u r g i a ,  A .  Z a m b o n ,  P .  Z a n o v e l l o ,  V .  B r o n t e ,  D .  
P i e t r o b o n  a n d  F .  D i  V i r g i l i o ,  J  I m m u n o l  1 4 9  ( 1 9 9 2 )  3 3 7 2 - 8 .  
[ 1 4 0 ]  R . E .  S o r g e ,  T .  T r a n g ,  R .  D o r f m a n ,  S . B .  S m i t h ,  S .  B e g g s ,  J .  
R i t c h i e ,  J . S .  A u s t i n ,  D . V .  Z a y k i n ,  H .  V a n d e r  M e u l e n ,  M .  
C o s t i g a n ,  T . A .  H e r b e r t ,  M .  Y a r k o n i - A b i t b u l ,  D .  T i c h a u e r ,  J .  
L i v n e h ,  E .  G e r s h o n ,  M .  Z h e n g ,  K .  T a n ,  S . L .  J o h n ,  G . D .  S l a d e ,  J .  
J o r d a n ,  C . J .  W o o l f ,  G .  P e l t z ,  W .  M a i x n e r ,  L .  D i a t c h e n k o ,  Z .  
S e l t z e r ,  M . W .  S a l t e r  a n d  J . S .  M o g i l ,  N a t  M e d  1 8  ( 2 0 1 2 )  5 9 5 - 9 .  
[ 1 4 1 ]  O .  S o d e r b e r g ,  M .  G u l l b e r g ,  M .  J a r v i u s ,  K .  R i d d e r s t r a l e ,  K . J .  
L e u c h o w i u s ,  J .  J a r v i u s ,  K .  W e s t e r ,  P .  H y d b r i n g ,  F .  B a h r a m ,  L . G .  
L a r s s o n  a n d  U .  L a n d e g r e n ,  N a t  M e t h o d s  3  ( 2 0 0 6 )  9 9 5 - 1 0 0 0 .  
[ 1 4 2 ]  P .  P e l e g r i n  a n d  A .  S u r p r e n a n t ,  E m b o  J  2 5  ( 2 0 0 6 )  5 0 7 1 - 8 2 .  
[ 1 4 3 ]  C .  M a r q u e s - d a - S i l v a ,  M . M .  C h a v e s ,  J . C .  R o d r i g u e s ,  S .  C o r t e -
R e a l ,  R .  C o u t i n h o - S i l v a  a n d  P . M .  P e r s e c h i n i ,  P L o S  O n e  6  ( 2 0 1 1 )  
e 2 5 3 5 6 .  
[ 1 4 4 ]  S . O .  S u a d i c a n i ,  R .  I g l e s i a s ,  J .  W a n g ,  G .  D a h l ,  D . C .  S p r a y  a n d  E .  
S c e m e s ,  G l i a  6 0  ( 2 0 1 2 )  1 1 0 6 - 1 6 .  
[ 1 4 5 ]  M .  M o n i f ,  C . A .  R e i d ,  K . L .  P o w e l l ,  M . L .  S m a r t  a n d  D . A .  
W i l l i a m s ,  J  N e u r o s c i  2 9  ( 2 0 0 9 )  3 7 8 1 - 9 1 .  
[ 1 4 6 ]  E .  A d i n o l f i ,  M .  C i r i l l o ,  R .  W o l t e r s d o r f ,  S .  F a l z o n i ,  P .  C h i o z z i ,  
P .  P e l l e g a t t i ,  M . G .  C a l l e g a r i ,  D .  S a n d o n a ,  F .  M a r k w a r d t ,  G .  
S c h m a l z i n g  a n d  F .  D i  V i r g i l i o ,  F a s e b  J  ( 2 0 1 0 ) .  
[ 1 4 7 ]  P .  P e l e g r i n ,  B r  J  P h a r m a c o l  1 6 3  ( 2 0 1 1 )  9 0 8 - 1 1 .  
[ 1 4 8 ]  C .  V i r g i n i o ,  A .  M a c K e n z i e ,  R . A .  N o r t h  a n d  A .  S u r p r e n a n t ,  J  
P h y s i o l  5 1 9  P t  2  ( 1 9 9 9 )  3 3 5 - 4 6 .  
[ 1 4 9 ]  V .  C o m p a n ,  L .  U l m a n n ,  O .  S t e l m a s h e n k o ,  J .  C h e m i n ,  S .  
C h a u m o n t  a n d  F .  R a s s e n d r e n ,  J  N e u r o s c i  3 2  ( 2 0 1 2 )  4 2 8 4 - 9 6 .  
[ 1 5 0 ]  B . S .  K h a k h ,  X . R .  B a o ,  C .  L a b a r c a  a n d  H . A .  L e s t e r ,  N a t  N e u r o s c i  
2  ( 1 9 9 9 )  3 2 2 - 3 0 .  
[ 1 5 1 ]  S .  C h a u m o n t  a n d  B . S .  K h a k h ,  P r o c  N a t l  A c a d  S c i  U  S  A  1 0 5  
( 2 0 0 8 )  1 2 0 6 3 - 8 .  
[ 1 5 2 ]  L . P .  B e r n i e r ,  A . R .  A s e ,  E .  B o u e - G r a b o t  a n d  P .  S e g u e l a ,  G l i a  6 0  
( 2 0 1 2 )  7 2 8 - 3 7 .  
[ 1 5 3 ]  M .  S o l l e ,  J .  L a b a s i ,  D . G .  P e r r e g a u x ,  E .  S t a m ,  N .  P e t r u s h o v a ,  
B . H .  K o l l e r ,  R . J .  G r i f f i t h s  a nd  C . A .  G a b e l ,  J  B i o l  C h e m  2 7 6  
( 2 0 0 1 )  1 2 5 - 3 2 .  
[ 1 5 4 ]  J . M .  L a b a s i ,  N .  P e t r u s h o v a ,  C .  D o n o v a n ,  S .  M c C u r d y ,  P .  L i r a ,  
M . M .  P a y e t t e ,  W .  B r i s s e t t e ,  J . R .  W i c k s ,  L .  A u d o l y  a n d  C . A .  
G a b e l ,  J  I m m u n o l  1 6 8  ( 2 0 0 2 )  6 4 3 6 - 4 5 .  
[ 1 5 5 ]  I . P .  C h e s s e l l ,  J . P .  H a t c h e r ,  C .  B o u n t r a ,  A . D .  M i c h e l ,  J . P .  
H u g h e s ,  P .  G r e e n ,  J .  E g e r t o n ,  M .  M u r f i n ,  J .  R i c h a r d s o n ,  W . L .  
P e c k ,  C . B .  G r a h a m e s ,  M . A .  C a s u l a ,  Y .  Y i a n g o u ,  R .  B i r c h ,  P .  
A n a n d  a n d  G . N .  B u e l l ,  P a i n  1 1 4  ( 2 0 0 5 )  3 8 6 - 9 6 .  
[ 1 5 6 ]  H .  H i d a k a  a n d  H .  Y o k o k u r a ,  A d v  P h a r m a c o l  3 6  ( 1 9 9 6 )  1 9 3 - 2 1 9 .  
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[ 1 5 7 ]  B . D .  H u m p h r e y s ,  C .  V i r g i n i o ,  A .  S u r p r e n a n t ,  J .  R i c e  a n d  G . R .  
D u b y a k ,  M o l  P h a r m a c o l  5 4  ( 1 9 9 8 )  2 2 - 3 2 .  
[ 1 5 8 ]  L . H .  J i a n g ,  A . B .  M a c k e n z i e ,  R . A .  N o r t h  a n d  A .  S u r p r e n a n t ,  M o l  
P h a r m a c o l  5 8  ( 2 0 0 0 )  8 2 - 8 .  
[ 1 5 9 ]  W .  P e n g ,  M . L .  C o t r i n a ,  X .  H a n ,  H .  Y u ,  L .  B e k a r ,  L .  B l u m ,  T .  
T a k a n o ,  G . F .  T i a n ,  S . A .  G o l d m a n  a n d  M .  N e d e r g a a r d ,  P r o c  N a t l  
A c a d  S c i  U  S  A  1 0 6  ( 2 0 0 9 )  1 2 4 8 9 - 9 3 .  
[ 1 6 0 ]  D .  Z h o u ,  M . L .  C h e n ,  Y . Q .  Z h a n g  a n d  Z . Q .  Z h a o ,  J  N e u r o s c i  3 0  
( 2 0 1 0 )  8 0 4 2 - 7 .  
[ 1 6 1 ]  E .  A d i n o l f i ,  L .  M e l c h i o r r i ,  S .  F a l z o n i ,  P .  C h i o z z i ,  A .  M o r e l l i ,  A .  
T i e g h i ,  A .  C u n e o ,  G .  C a s t o l d i ,  F .  D i  V i r g i l i o  a n d  O . R .  B a r i c o r d i ,  
B l o o d  9 9  ( 2 0 0 2 )  7 0 6 - 8 .  
[ 1 6 2 ]  J . H .  C h o n g ,  G . G .  Z h e n g ,  Y . Y .  M a ,  H . Y .  Z h a n g ,  K .  N i e ,  Y . M .  L i n  
a n d  K . F .  W u ,  J  B i o l  C h e m  2 8 5  ( 2 0 1 0 )  3 6 1 7 9 - 8 7 .  
[ 1 6 3 ]  B .  J e l a s s i ,  A .  C ha n t o m e ,  F .  A l c a r a z - P e r e z ,  A .  B a r o j a - M a z o ,  M . L .  
C a y u e l a ,  P .  P e l e g r i n ,  A .  S u r p r e n a n t  a n d  S .  R o g e r ,  O n c o g e n e  3 0  
( 2 0 1 1 )  2 1 0 8 - 2 2 .  
[ 1 6 4 ]  M .  K o y a m a ,  T . R .  K e l l y  a n d  K . A .  W a t a n a b e ,  J  M e d  C h e m  3 1  
( 1 9 8 8 )  2 8 3 - 4 .  
[ 1 6 5 ]  Y . Y .  C h e n ,  S . Y .  C h i a n g ,  J . G .  L i n ,  Y . S .  M a ,  C . L .  L i a o ,  S . W .  
W e n g ,  T . Y .  L a i  a n d  J . G .  C h u n g ,  I n t  J  O n c o l  3 6  ( 2 0 1 0 )  1 1 1 3 - 2 0 .  
[ 1 6 6 ]  C .  T a b o l a c c i ,  A .  L e n t i n i ,  P .  M a t t i o l i ,  B .  P r o v e n z a n o ,  S .  
O l i v e r i o ,  F .  C a r l o m o s t i  a n d  S .  B e n i n a t i ,  L i f e  S c i  8 7  ( 2 0 1 0 )  3 1 6 -
2 4 .  
[ 1 6 7 ]  L .  L i u ,  J .  Z o u ,  X .  L i u ,  L . H .  J i a n g  a n d  J .  L i ,  E u r  J  P h a r m a c o l  6 4 0  
( 2 0 1 0 )  1 5 - 9 .  
[ 1 6 8 ]  A .  M a c K e n z i e ,  H . L .  W i l s o n ,  E .  K i s s - T o t h ,  S . K .  D o w e r ,  R . A .  
N o r t h  a n d  A .  S u r p r e n a n t ,  I m m u n i t y  1 5  ( 2 0 0 1 )  8 2 5 - 3 5 .  
[ 1 6 9 ]  A . B .  M a c k e n z i e ,  M . T .  Y o u n g ,  E .  A d i n o l f i  a n d  A .  S u r p r e n a n t ,  J  
B i o l  C h e m  2 8 0  ( 2 0 0 5 )  3 3 9 6 8 - 7 6 .  
[ 1 7 0 ]  H . P .  B u i s m a n ,  T . H .  S t e i n b e r g ,  J .  F i s c h b a r g ,  S . C .  S i l v e r s t e i n ,  
S . A .  V o g e l z a n g ,  C .  I n c e ,  D . L .  Y p e y  a n d  P . C .  L e i j h ,  P r o c  N a t l  
A c a d  S c i  U  S  A  8 5  ( 1 9 8 8 )  7 9 8 8 - 9 2 .  
[ 1 7 1 ]  L . C .  N u t t l e  a n d  G . R .  D u b y a k ,  J  B i o l  C h e m  2 6 9  ( 1 9 9 4 )  1 3 9 8 8 - 9 6 .  
[ 1 7 2 ]  D . K .  B l a n c h a r d ,  S .  W e i ,  C .  D u a n ,  F .  P e r i c l e ,  J . I .  D i a z  a n d  J . Y .  
D j e u ,  B l o o d  8 5  ( 1 9 9 5 )  3 1 7 3 - 8 2 .  
[ 1 7 3 ]  F .  D i  V i r g i l i o ,  P .  P i z z o ,  P .  Z a n o v e l l o ,  V .  B r o n t e  a n d  D .  C o l l a v o ,  
I m m u n o l  T o d a y  1 1  ( 1 9 9 0 )  2 7 4 - 7 .  
[ 1 7 4 ]  F .  D i  V i r g i l i o ,  P .  C h i o z z i ,  S .  F a l z o n i ,  D .  F e r r a r i ,  J . M .  S a n z ,  V .  
V e n k e t a r a m a n  a n d  O . R .  B a r i c o r d i ,  C e l l  D e a t h  D i f f e r  5  ( 1 9 9 8 )  
1 9 1 - 9 .  
[ 1 7 5 ]  P .  P e l e g r i n  a n d  A .  S u r p r e n a n t ,  E m b o  J  2 8  ( 2 0 0 9 )  2 1 1 4 - 2 7 .  
[ 1 7 6 ]  M .  S l a t e r ,  S .  D a n i e l e t t o ,  M .  P o o l e y ,  L .  C h e n g  T e h ,  A .  G i d l e y -
B a i r d  a n d  J . A .  B a r d e n ,  B r e a s t  C a n c e r  R e s  T r e a t  8 3  ( 2 0 0 4 )  1 - 1 0 .  
[ 1 7 7 ]  M .  T a f a n i ,  M .  D i  V i t o ,  A .  F r a t i ,  L .  P e l l e g r i n i ,  E .  D e  S a n t i s ,  G .  
S e t t e ,  A .  E r a m o ,  P .  S a l e ,  E .  M a r i ,  A .  S a n t o r o ,  A .  R a c o ,  M .  
S a l v a t i ,  R .  D e  M a r i a  a n d  M . A .  R u s s o ,  J  N e u r o i n f l a m m a t i o n  8  
( 2 0 1 3 )  3 2 .  
[ 1 7 8 ]  X .  L i ,  X .  Q i ,  L .  Z h o u ,  W .  F u ,  F . W .  A b d u l - K a r i m ,  G .  M a c l e n n a n  
a n d  G . I .  G o r o d e s k i ,  P u r i n e r g i c  S i g n a l  5  ( 2 0 0 9 )  3 5 1 - 6 8 .  
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[ 1 7 9 ]  S .  H u a n g ,  Y .  C h e n ,  W .  W u ,  N .  O u y a n g ,  J .  C h e n ,  H .  L i ,  X .  L i u ,  F .  
S u ,  L .  L i n  a n d  Y .  Y a o ,  P L o S  O n e  8  ( 2 0 1 3 )  e 8 0 7 0 7 .  
[ 1 8 0 ]  M .  S l a t e r ,  S .  D a n i e l e t t o ,  A .  G i d l e y - B a i r d ,  L . C .  T e h  a n d  J . A .  
B a r d e n ,  H i s t o p a t h o l o g y  4 4  ( 2 0 0 4 )  2 0 6 - 1 5 .  
[ 1 8 1 ]  M .  S l a t e r ,  S .  D a n i e l e t t o  a n d  J . A .  B a r d e n ,  J  M o l  H i s t o l  3 6  ( 2 0 0 5 )  
1 5 9 - 6 5 .  
[ 1 8 2 ]  L .  R a v e n n a ,  P .  S a l e ,  M .  D i  V i t o ,  A .  R u s s o ,  L .  S a l v a t o r i ,  M .  
T a f a n i ,  E .  M a r i ,  S .  S e n t i n e l l i ,  E .  P e t r a n g e l i ,  M .  G a l l u c c i ,  F .  D i  
S i l v e r i o  a n d  M . A .  R u s s o ,  P r o s t a t e  6 9  ( 2 0 0 9 )  1 2 4 5 - 5 5 .  
[ 1 8 3 ]  E .  T a k a i ,  M .  T s u k i m o t o ,  H .  H a r a d a ,  K .  S a w a d a ,  Y .  M o r i y a m a  a n d  
S .  K o j i m a ,  J  C e l l  S c i  1 2 5  ( 2 0 1 2 )  5 0 5 1 - 6 0 .  
[ 1 8 4 ]  E .  T a k a i ,  M .  T s u k i m o t o ,  H .  H a r a d a  a n d  S .  K o j i m a ,  P u r i n e r g i c  
S i g n a l  ( 2 0 1 4 ) .  
[ 1 8 5 ]  B . M .  K u n z l i ,  P . O .  B e r b e r a t ,  T .  G i e s e ,  E .  C s i z m a d i a ,  E .  
K a c z m a r e k ,  C .  B a k e r ,  I .  H a l a c e l i ,  M . W .  B u c h l e r ,  H .  F r i e s s  a n d  
S . C .  R o b s o n ,  A m  J  P h y s i o l  G a s t r o i n t e s t  L i v e r  P h y s i o l  2 9 2  ( 2 0 0 7 )  
G 2 2 3 - 3 0 .  
[ 1 8 6 ]  A .  S o l i n i ,  S .  C u c c a t o ,  D .  F e r r a r i ,  E .  S a n t i n i ,  S .  G u l i n e l l i ,  M . G .  
C a l l e g a r i ,  A .  D a r d a n o ,  P .  F a v i a n a ,  S .  M a d e c ,  F .  D i  V i r g i l i o  a n d  
F .  M o n z a n i ,  E n d o c r i n o l o g y  1 4 9  ( 2 0 0 8 )  3 8 9 - 9 6 .  
[ 1 8 7 ]  R . M .  R u g g e r i ,  D .  V i l l a r i ,  A .  S i m o n e ,  R .  S c a r f i ,  M .  A t t a r d ,  F .  
O r l a n d i ,  G .  B a r r e s i ,  F .  T r i m a r c h i ,  M .  T r o v a t o  a n d  S .  B e n v e n g a ,  J  
E n d o c r i n o l  I n v e s t  2 5  ( 2 0 0 2 )  9 5 9 - 6 6 .  
[ 1 8 8 ]  L . Q .  G u ,  F . Y .  L i ,  L .  Z h a o ,  Y .  L i u ,  Q .  C h u ,  X . X .  Z a n g ,  J . M .  L i u ,  
G .  N i n g  a n d  Y . J .  Z h a o ,  E n d o c r i n e  3 8  ( 2 0 1 0 )  2 7 6 - 8 2 .  
[ 1 8 9 ]  J . H .  K w o n ,  E . S .  N a m ,  H . S .  S h i n ,  S . J .  C h o ,  H . R .  P a r k  a n d  M . J .  
K w o n ,  K o r e a n  J  P a t h o l  4 8  ( 2 0 1 4 )  3 0 - 5 .  
[ 1 9 0 ]  A . V .  G r e i g ,  C .  L i n g e ,  V .  H e a l y ,  P .  L i m ,  E .  C l a y t o n ,  M . H .  
R u s t i n ,  D . A .  M c G r o u t h e r  a n d  G .  B u r n s t o c k ,  J  I n v e s t  D e r m a t o l  
1 2 1  ( 2 0 0 3 )  3 1 5 - 2 7 .  
[ 1 9 1 ]  M .  S l a t e r ,  R . A .  S c o l y e r ,  A .  G i d l e y - B a i r d ,  J . F .  T h o m p s o n  a n d  
J . A .  B a r d e n ,  M e l a n o m a  R e s  1 3  ( 2 0 0 3 )  1 3 7 - 4 5 .  
[ 1 9 2 ]  F .  H a t t o r i ,  Y .  O h s h i m a ,  S .  S e k i ,  M .  T s u k i m o t o ,  M .  S a t o ,  T .  
T a k e n o u c h i ,  A .  S u z u k i ,  E .  T a k a i ,  H .  K i t a n i ,  H .  H a r a d a  a n d  S .  
K o j i m a ,  E u r  J  P h a r m a c o l  6 9 5  ( 2 0 1 2 )  2 0 - 6 .  
[ 1 9 3 ]  S .  B i a n ,  X .  S u n ,  A .  B a i ,  C .  Z h a n g ,  L .  L i ,  K .  E n j y o j i ,  W . G .  
J u n g e r ,  S . C .  R o b s o n  a n d  Y .  W u ,  P L o S  O n e  8  ( 2 0 1 3 )  e 6 0 1 8 4 .  
[ 1 9 4 ]  M . P .  G e h r i n g ,  T . C .  P e r e i r a ,  R . F .  Z a n i n ,  M . C .  B o r g e s ,  A .  B r a g a  
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 1 
Table 1: P2X7 expression, functionality and postulated roles in solid tumours 
Expression of P2X7 mRNA was assessed by PCR, and P2X7 proteins by immunohistochemistry (IHC), western blotting (WB) or Flow 
cytometry (FC). 
 
Cancer 
types 
Samples: biopsies / 
cells 
(h, human ; m, mouse ; 
r, rat) 
Expression 
(mRNA, 
proteins, 
variants) 
Functionality 
of P2X7 at the 
plasma 
membrane 
Cellular effects of 
P2X7 
agonist/antagonists  
Postulated role References 
Breast 
cancer 
Human biopsies of in 
situ or invasive 
lobular or ductal 
breast carcinoma 
 
Human lobular or 
ductal breast 
carcinoma 
 
MDA-MB-435s (h) 
 
 
 
MDA-MB-231 (h) 
 
 
 
 
 
MCF7 (h) 
 
 
Py8119 (m) 
Protein (IHC) 
 
 
 
 
Protein (IHC) 
 
 
 
mRNA, proteins 
(WB), P2X7A. 
 
 
Proteins (WB) 
Proteins (WB) 
mRNA, protein 
(WB) 
 
 
mRNA 
Proteins, variant ? 
 
mRNA 
 
Not assessed 
 
 
 
 
Not assessed 
 
 
 
Current, [Ca2+]i, 
dye uptake 
 
 
Not assessed  
Not assessed  
Not assessed  
 
 
 
No current 
Not assessed 
 
Not assessed 
- 
 
 
 
 
- 
 
 
 
Yes (ATP / KN62, 
A438079, A740003, 
emodin) 
 
Not assessed 
Yes (BzATP / - ) 
Yes (ATPJS / oATP) 
 
 
 
Not identified 
Not assessed 
 
Yes (ATPJS / - ) 
Early marker  
 
 
 
 
Apoptosis 
 
 
 
Cancer cell  
migration and 
invasiveness 
 
Apoptosis  
Invasion 
Inhibition of 
migration and 
growth 
 
Not identified 
Apoptosis 
 
Inhibition of 
migration and 
[176] 
 
 
 
 
[178] 
 
 
 
[132, 163] 
 
 
 
[179] 
[177] 
[219] 
 
 
 
[34] 
[179] 
  
[219] 
  
 2 
tumour growth  
Prostate 
Cancer 
Human cancer 
biopsies 
 
Laser-capture 
microdissected 
biopsies 
 
PC-3 (h) 
 
PC-3 (h) , DU-145(h) 
 
 
PC-3(h) 
Protein (IHC) 
 
 
mRNA, proteins 
(IHC, WB) 
 
 
mRNA, proteins 
(WB) 
- 
 
 
mRNA 
Not assessed 
 
 
Not assessed 
 
 
 
Not assessed 
 
Not assessed 
 
 
No lucifer 
yellow uptake 
 
- 
 
 
-  
 
 
 
Not assessed 
 
Yes (ATP/KN-62) 
 
 
Yes (ATP / - )  
Early marker 
 
 
Cancer marker 
 
 
 
Not identified  
 
Cancer cell 
invasiveness 
 
Not identified 
[180] 
[181] 
 
[182] 
 
 
 
[212] 
 
[109] 
 
 
[241] 
Lung 
Cancer 
A549 (h), PC-9(h), 
H292 (h) 
mRNA, protein 
(WB) 
Ethidium 
uptake 
Yes (ATP, 
BzATP/A438079, 
emodin) 
Cancer cell 
migration and 
invasiveness 
 
[132, 183, 184] 
Pancreatic 
cancer 
Human biopsies 
 
mRNA, protein 
(IHC) 
 
Not assessed 
 
Not assessed 
 
Not identified [185] 
Papilliary 
thyroid 
cancer 
(PTC) 
Human PTC biopsies 
FB1 (h), FB2 (h) 
 
 
Human PTC biopsies 
 
 
Human PTC biopsies 
 
mRNA, protein 
(IHC, WB) 
 
 
Protein (IHC) 
 
 
Protein (IHC) 
 
Not assessed 
[Ca2+]i 
 
 
Not assessed 
 
 
Not assessed 
 
- 
Yes (ATP, BzATP / 
oATP, KN-62) 
 
- 
 
 
- 
 
Trophic activity 
through IL-6 
release  
 
Cancer 
aggressiveness 
 
Poor prognosis 
 
[186] 
[186] 
 
 
[188] 
 
 
[189] 
 
 3 
Human PTC biopsies 
 
Full-length 
protein (IHC) 
 
Not assessed - - [178] 
Skin 
cancers 
Non-melanoma 
Necrotic/aptotic areas 
of basal cell and 
suqmous cell 
carcinomas 
 
A431 (h) 
 
Melanoma 
 
Human biopsies 
 
Human biopsies 
 
 
A375 (h) 
 
 
Skmel28 (h) , Bris 
(h), HBL (h), 518A2 
(h) 
 
 
B16 (m) 
 
 
 
 
B16 (m) 
 
Protein (IHC) 
 
 
 
 
Protein (IHC) 
 
 
 
Protein (IHC) 
 
Protein (IHC), 
P2X7A ? 
 
mRNA, protein 
(IHC), P2X7A ? 
 
mRNA 
 
 
 
 
mRNA, protein 
(WB) 
 
 
 
mRNA, P2X7a 
 
Not assessed 
 
 
 
 
Not assessed 
 
 
 
Not assessed 
 
Not assessed 
 
 
YO-PRO-1 
uptake 
 
Not assessed 
 
 
 
 
Ethidium 
uptake 
 
 
 
Ethidium 
 
- 
 
 
 
 
Yes (ATP, ATPJS, 
BzATP) 
 
 
- 
 
- 
 
 
Yes (BzATP / KN-
62) 
 
Not assessed 
 
 
 
 
Yes (ATP/A438079, 
oATP) 
 
 
 
Yes (ATP / -) 
 
Apoptosis 
 
 
 
 
Apoptosis 
 
 
 
Apoptosis 
 
Apoptosis 
 
 
Apoptosis 
 
 
Not identified 
 
 
 
 
ATP release and 
subsquent cell 
proliferation 
 
 
Cell death 
 
[190] 
 
 
 
 
[190] 
 
 
 
[191] 
 
[30] 
 
 
[30] 
 
 
Figure 2, this review 
 
 
 
 
[192] 
[204] 
 
 
 
[193] 
 4 
 
 
B16 (m) 
variant 
 
mRNA, protein 
(WB) 
 
uptake 
 
Not assessed 
 
 
Yes (ATP,BzATP / 
KN-62) 
 
 
Apoptosis 
 
 
 
[218] 
Brain 
cancers 
Neuroblastoma 
 
Human biopsies 
 
 
GI-CA-N (h), HTLA-
230 (h), GI-ME-N 
(h), LAN-5 (h), 
LAN-1 (h), SK-N-
BE-2 (h) and SH-SY-
5Y (h) 
 
ACN (h)  
 
 
 
 
Neuro-2a (m) 
 
 
 
Neuro-2a (m) 
 
 
 
Glioma 
 
 
 
Protein (IHC), 
P2X7A ? 
 
Protein (IHC), 
P2X7A ? 
 
 
 
 
 
Protein (IHC), 
P2X7A ? 
 
 
 
mRNA, protein 
(WB) 
 
 
mRNA, protein 
(WB, IHC) 
 
 
 
 
 
 
- 
 
 
Not assessed 
 
 
 
 
 
 
[Ca2+]i, YO-
PRO-1 uptake 
 
 
 
[Ca2+]i 
 
 
 
Current, [Ca2+]i 
 
 
 
 
 
 
 
- 
 
 
Not assessed 
 
 
 
 
 
 
Yes (ATP, BzATP / 
KN-62) 
 
 
 
Yes (ATP / oATP, 
BBG, A438079) 
 
 
Yes (ATP, BzATP / 
KN-62, BBG, 
A438079) 
 
 
 
 
 
- 
 
 
- 
 
 
 
 
 
 
Substance P-
dependent 
proliferation 
 
 
Cell survival 
 
 
 
Undifferentiated 
proliferative 
phenotype 
 
 
 
 
 
[42] 
 
 
[42] 
 
 
 
 
 
 
[42] 
 
 
 
 
[205] 
 
 
 
[206] 
 
 
 
 
 
 5 
C6 (r) 
 
 
 
C6 (r) 
 
 
 
 
GL261 (m) 
 
 
 
U-138MG (h), U-
251MG (h) 
 
M059J (h) 
 
mRNA, protein 
(WB, IHC) 
 
 
mRNA, protein 
(WB, IHC) 
 
 
 
mRNA, protein 
(WB) 
 
 
mRNA, protein 
(FC) 
 
mRNA, protein 
(FC) 
[Ca2+]i, 
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Figure legends 
 
Figure 1:  Chemical structures of representative small molecular weight P2X7 receptor 
selective antagonists developed from medicine chemistry.  
(A), tetrazole/trizole-based compounds A-438079 and A-83997. (B), cyanoguanidine 
derivatives A-740003, A-759029 and A-804598. (C), adamantane amide AZ10606120. (D), 
cyclic imide AZ11645373. (E), azauracil derivative CE-224535. The concentration inhibiting 
by 50% agonist-induced human P2X7 receptor responses (increases in the cytosolic Ca2+, 
ionic currents or fluorescent dye uptake) or IC50 value is shown in brackets. 
 
 
Figure 2: Expression profile of P2 receptors in human melanoma cancer cell lines.   
Representative RT-PCR experiments analysing the expression of mRNA for all the P2X 
receptors, and showing the expression of P2X7 in Skmel28, Bris, HBL and 518A2 melanoma 
cells. Cells were grown in Dulbeccos modified Eagles medium (DMEM), supplemented 
with 10% foetal calf serum. Reverse transcription-PCR experiments were done using standard 
protocols and PCR primers indicated in our previous publication [119]. Briefly, the 
temperature profile for PCR was 4 min at 94ƕC followed by amplification for 40 cycles, each 
consisting of 1 min at 94ƕC, 30 s at 60ƕC, and 1 min at 72ƕC and a final extension for 2 min at 
72ƕC. PCR products were analyzed by electrophoresis in 1.8%-agarose gels containing 
ethidium bromide, and visualized by UV trans-illumination. 
 
 
  
Figure 3: Schematic representation of the participation of P2X7 receptor in epithelial 
cancer cell biology. 
(A) In epithelial cancer cells, the autocrine/paracrine release of ATP, through transmembrane 
diffusion or vesicular release is responsible for a pericellular halo that activates P2X7 into a 
basal mode activity, with no or weak membrane permeabilization, thus increasing cell 
metabolism and promoting cell proliferation, migration and invasiveness. These properties 
would promote tumour growth and progression towards metastatic steps. (B) The exogenous 
stimulation with high concentrations of ATP or BzATP would tend to overactivate P2X7 
receptors into a cytolytic mode, due to the high increase of intracellular Ca2+ concentration 
and to the membrane permeabilization. This would induce cancer cell apoptosis. 
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